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ABSTRACT 
LAUREN NEIGHBOURS: The Protective and Pathologic Roles of Toll-like Receptors in 
Arthritogenic Alphavirus Infection 
(Under the direction of Mark T. Heise) 
 
 Arthritogenic alphaviruses, including Chikungunya virus and Ross River virus 
(RRV), are mosquito-borne pathogens responsible for epidemics of debilitating 
polyarthritis in humans. The host inflammatory response plays an important role in the 
pathogenesis of arthritic alphaviruses, where some pathways, such as the complement 
cascade, exacerbate virus-induced disease, while type I IFN and other immune signaling 
pathways mediate protection from disease. Using a mouse model of alphavirus-induced 
arthritis/myositis, we demonstrated that toll-like receptor (TLR) signaling contributes to 
protection from and enhancement of alphavirus-induced disease. Myd88-dependent 
TLR7 signaling was critical for protection from severe RRV-induced morbidity and 
mortality. Additionally, TLR7 deficiency resulted in the production of low affinity, non-
neutralizing RRV-specific antibodies that exacerbated virus-induced disease through 
systemic antibody- and complement-mediated mechanisms. Furthermore, TLR4 
promoted RRV-induced morbidity and tissue damage in a complement-dependent 
manner, and complement-associated macrophage activation was dependent on TLR4 
expression during RRV infection. Taken together, these studies establish the integral role 
that TLR pathways play in arthritic alphavirus pathogenesis. 
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CHAPTER ONE: 
INTRODUCTION 
Overview of alphaviruses 
 
Alphavirus taxonomy 
Alphaviruses are positive-sense single-stranded RNA (ssRNA) arboviruses and 
are members of the family Togaviridae (1). The Togaviridae family consists of two 
genera, Alphavirus and Rubivirus, and 29 of the 30 species of togaviruses are 
alphaviruses, with Rubella virus being the only identified rubivirus (1). Alphaviruses and 
other arboviruses were originally grouped according to their antigenicity as determined 
using various serological and biochemical assays (2). Modern technological advances 
have expanded the classification of alphaviruses into distinct clades by comparing the 
genomic sequences of the viral species, which adds a complex genetic and evolutionary 
dimension to the taxonomy (3).  
 Alphaviruses are categorized into two groups, Old World and New World, which 
distinguish the viruses based on their geographic distribution and epidemiological 
characteristics (3). The Old World alphaviruses, including Ross River virus (RRV), 
chikungunya virus (CHIKV), and Sindbis virus (SINV), are associated with debilitating 
arthralgia and myalgia, while New World alphaviruses such as Venezuelan equine 
encephalitis virus (VEEV), eastern equine encephalitis (EEE) virus, and western equine 
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encephalitis (WEE) virus induce encephalitis (4, 5). Old World and New World 
alphaviruses are further segregated into seven distinct antigenic complexes or clades, 
including the Barmah Forest, Semliki Forest, Venezuelan equine encephalitis (VEE), 
EEE, WEE, Trocara, Middelburg, and Ndumu clades (1). An overview of alphavirus 
classification and epidemiology is included in Table 1, which focuses on Old World 
Alphavirus taxonomy 
Alphaviruses are positive-sense single-stranded RNA (ssRNA) arboviruses and 
are members of the family Togaviridae (1). The Togaviridae family consists of two 
genera, Alphavirus and Rubivirus, and 29 of the 30 species of togaviruses are 
alphaviruses, with Rubella virus being the only identified rubivirus (1). Alphaviruses and 
other arboviruses were originally grouped according to their antigenicity as determined 
using various serological and biochemical assays (2). Modern technological advances 
have expanded the classification of alphaviruses into distinct clades by comparing the 
genomic sequences of the viral species, which adds a complex genetic and evolutionary 
dimension to the taxonomy (3).  
 Alphaviruses are categorized into two groups, Old World and New World, which 
distinguish the viruses based on their geographic distribution and epidemiological 
characteristics (3). The Old World alphaviruses, including Ross River virus (RRV), 
chikungunya virus (CHIKV), and Sindbis virus (SINV), are associated with debilitating 
arthralgia and myalgia, while New World alphaviruses such as Venezuelan equine 
encephalitis virus (VEEV), eastern equine encephalitis (EEE) virus, and western equine 
encephalitis (WEE) virus induce encephalitis (4, 5). Old World and New World 
alphaviruses are further segregated into seven distinct antigenic complexes or clades, 
3 
 
including the Barmah Forest, Semliki Forest, Venezuelan equine encephalitis (VEE), 
EEE, WEE, Trocara, Middelburg, and Ndumu clades (1). An overview of alphavirus 
classification and epidemiology is included in Table 1, which focuses on Old World 
arthritogenic alphaviruses for the purposes of this work and was adapted with permission 
from Weaver and colleagues (1).  
Alphavirus emergence and transmission 
 Alphaviruses are vector-borne viruses that cause a variety of diseases in humans, 
other vertebrates, and fish (1). Most alphaviruses are transmitted to their vertebrate hosts 
by mosquito vectors, and viral transmission is primarily maintained within an enzootic 
cycle via Culex and Aedes mosquito species that inhabit humid, marshy regions (1). As 
depicted in Figure 1.1, the enzootic transmission cycle of alphaviruses allows for 
maintenance of viral infection in zoonotic reservoir hosts with endemic disease occurring 
in certain geographic areas (Figure 1.1, which was adapted with permission from Weaver 
and colleagues)(1). However, alphaviruses also cause sporadic epidemics that can lead to 
widespread morbidity and mortality in humans (Figure 1.1) (4). Most epidemics 
involving New World alphaviruses, including VEE, EEE, and WEE viruses, have 
occurred in South, Central, and North America (5). Alternatively, Old World alphavirus 
epidemics have occurred in Africa, Asia, and Australia, with cases recently spreading to 
Europe and the United States after infected individuals traveled to endemic regions (6-8).  
Because of the pronounced morbidity and explosive epidemics associated with 
infections, CHIKV is considered a high-risk emerging pathogen that poses significant 
global threats to public health (9). The first cases of CHIKV were identified in the 1950s 
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in Africa, where the virus is believed to have originated, and the virus caused multiple 
outbreaks through the 1980s in Africa and Southeast Asia (10). However, CHIKV 
outbreaks have re-emerged and expanded with widespread distribution since 2004, with 
thousands to millions of infections presenting with persistent debilitating arthraligia and a 
case fatality rate estimated at approximately 0.1% (1, 11). Additionally, the regions 
where CHIKV outbreaks tend to occur are also endemic for tropical diseases with similar 
symptomatic presentations such as dengue virus fever and malaria, and CHIKV 
infections are thus believed to be grossly underreported (12). Epidemics of CHIKV-like 
disease, which were characterized as dengue outbreaks but were likely caused by 
CHIKV, have been traced back as far as the 19
th
 century (13). Moreover, genotyping of 
viral isolates from the La Réunion outbreak of 2005-2007 identified a mutation in the 
CHIKV strain that allowed more efficient transmission by Aedes Albopictus mosquitoes 
and resulted in rapid dissemination of the virus (11). 
Increasing cases of endemic and epidemic disease induced by other arthritogenic 
alphaviruses such as RRV and Barmah Forest virus (BFV) have also spurred recent 
concerns (14). RRV, which results in over 4,000 cases of disease in Australia every year, 
is considered the most substantial arboviral threat to public health in the Australasian 
region because of the long-lasting morbidities associated with infections (14, 15). RRV 
was first isolated in 1959 from mosquitoes found near the Australian Ross River, and it 
was the causative agent of a 1979 epidemic in the South Pacific that resulted in over 
60,000 cases of disease (16). BFV results in approximately 1,000 human cases of disease 
in Australia each year, with symptoms typically less severe and shorter than those 
induced by RRV or CHIKV (17). However, the recent rise in BFV infections have 
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concerned Australian public health authorities, and the growing number of arthritogenic 
alphavirus cases in the Australasian region results in a considerable economic burden as 
well (14). Moreover, models of climate change in alphavirus-endemic regions have 
predicted that alterations in environmental conditions, such as increasing rainfall and 
temperatures, may result in enhanced alphavirus activity and thus escalate the risk of 
human infections (14, 18).  
Virus organization and life cycle 
 Alphaviruses are enveloped viruses of approximately 70 nm in diameter and 
contain an ssRNA genome of approximately 12 Kb in length (19-21). The virion contains 
a host-derived lipid membrane, which is embedded with heterodimeric trimer spikes 
formed by the highly glycosylated E1 and E2 viral glycoproteins (22). Within the 
membrane-bound virion is an icosahedral nucleocapsid, which is formed by the viral 
capsid proteins. The alphavirus genome encodes two open reading frames, from which 
the four nonstructural proteins (NSPs) are encoded from the genomic RNA and the five 
structural proteins are encoded from the 26S subgenomic strand (23). The genomic and 
subgenomic RNA species contain a 5’ methylguanosine cap and 3’ polyadenylated tail, 
and each strand is initially translated into polyproteins before being cleaved 
posttranslationally by viral and host proteases. A simplified schematic of the alphavirus 
genome, which was adapted with permission from Weaver and colleagues, can be found 
in Figure 1.2 (1).  
 Entry of alphaviruses is generally considered to occur via clathrin- and receptor-
mediated endocytosis, although reports of entry via direct viral fusion with the plasma 
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membrane have also been reported (23). Upon receptor-mediated endocytosis of the 
virion, viral uncoating occurs to allow for the release of alphavirus ssRNA into the 
cytoplasm. The initial translation of the viral RNA, which is infectious upon entry, results 
in the formation of the NSP polyprotein, NSP1234 and structural polyproteins (24). 
Cleavage of NSP1234 into NSP123 and NSP4 allow for the formation of the replication 
complex, which synthesizes the negative strand RNA, and complete cleavage of the 
nonstructural proteins allows for the complete stable replication complex to be formed 
and initiates positive full-length and subgenomic RNA synthesis (23). Cleavage of the 
structural polyprotein releases the capsid protein, which associates with the newly 
transcribed viral RNA and facilitates packaging of the RNA into nucleocapsid vesicles 
(25). A signaling sequence on the E3 protein facilitates the relocation of the remaining 
structural polyprotein to relocate and bud into the endoplasmic reticulum (ER) for further 
processing by host proteases, while 6K facilitates downstream processing of the E1 
glycoprotein and aids in viral budding (23). E1 and E2 interact shortly after synthesis to 
form dimers, which are transported from the ER-Golgi complex to the host plasma 
membrane (26). The nucleocapsids formed in the cytoplasm can then bud into the host 
membrane containing E1-E2 spikes and release envelope-containing particles (22).  
In addition to their roles in replication and structural formation, alphavirus 
proteins are also involved in viral pathogenesis. NSP1, which mediates capping and 
methylation of viral RNA, regulates host inflammatory responses to alphavirus infection 
(22, 27, 28). Mutations in NSP1 of RRV resulted in reduced tissue damage in infected 
mice, and a virulence determinant within RRV and SINV was demonstrated to modulate 
type I interferon (IFN) responses and disrupt JAK/STAT signaling (27-29). NSP2, which 
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has numerous enzymatic activities and functions, performs multiple roles during 
replication and packaging but also mediates cellular cytopathic effects (CPE), induces 
host shut-off and antagonizes type I/II type I IFN induction during infection (30-33). 
Additionally, the use of NSP2 as an adjuvant in a CHIKV DNA vaccine enhanced 
protection of mice challenged with CHIKV when compared to mice immunized with the 
vaccine alone (34). Little is known about the functions of NSP3, which is required for 
RNA synthesis (22). However, NSP3 plays a role in neurovirulence and in the 
suppression of stress granule formation, and it may also influence vector specificity (35-
38). The viral RNA-dependent RNA polymerase, NSP4, is proposed to have multiple 
functions during RNA replication and was recently reported to modulate the host 
translational machinery to enable more efficient replication during CHIKV infection (22, 
39). Aside from their roles in virus entry and assembly, the structural proteins are also 
important mediators of viral pathogenesis. The precursor E2 protein is involved in RRV-
induced inflammatory disease, while the glycans on the E1 and E2 glycoproteins 
modulate type I IFN production and mediate pathogenesis during RRV infection [(27, 
40), Gunn and Heise, unpublished]. 
 
1.1 Human infection and animal models of disease 
 
Pathogenesis of human arthritogenic alphavirus infection 
 Most human infections with Old World alphaviruses such as CHIKV and RRV 
result in mild “flu-like” symptoms of fever, headache, rash and malaise that usually 
dissipate within a week (15). However, a significant subset of infected individuals 
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develop a debilitating polyarthralgia and myalgia that can last for several months and in 
rare cases can induce chronic disease or mortality (41, 42). Chikungunya virus, which is 
named for the Makonde Tanzanian term for “that which bends up,” is considered the 
most threating arthritogenic alphavirus to global public health because of its capacity to 
induce catastrophic epidemics and persistent disease (43). Severe cases of arthritogenic 
disease tend to occur in individuals with chronic underlying conditions such as diabetes 
or impaired kidney function or in patients that have adverse reactions to therapeutic drug 
treatment (43). Chronic pain associated with arthritogenic alphavirus infection can 
significantly impact the quality of life of infected individuals and results in a substantial 
economic burden in affected regions because of prolonged care and decreased 
productivity (14, 44, 45).  
The incubation period of the virus is usually between 2-14 days prior to the onset 
of symptoms, with a viremia that lasts approximately 5-7 days (1, 15). The virus 
replicates in skeletal muscle and joint tissues during the acute infection, although RNA 
and viral proteins were found in various tissues and synovial macrophages for several 
weeks to months following the resolution of viral replication (41, 46). The pathology 
induced by arthritogenic alphavirus infection is believed to be mediated by host 
inflammatory responses induced by viral replication or viral products, although these are 
not considered autoimmune responses (15).   
Although relatively rare, mother-to-child transmission can occur with CHIKV 
infection (42). A prospective study, which was conducted to determine the prevalence of 
CHIKV vertical transmission following the La Réunion outbreak in 2005, found that 
approximately 10% of the neonates were exposed to CHIKV during pregnancy, and 2.5% 
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of the exposed neonates became infected with CHIKV (47). All of the infected neonates 
developed symptoms of infection shortly after birth, and more than half of the infected 
neonates developed severe neurological disease including encephalopathy and persistent 
neurodevelopmental disabilities. Transmission rates of CHIKV were highest in mothers 
that were infected very late during pregnancy, although infection may have contributed to 
early fetal deaths that were also observed.  
There are currently no effective treatments or vaccines available for arthritogenic 
alphavirus infections. The current treatment regimen typically consists of treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs) and/or steroids (41, 42). Anti-rheumatic 
drugs, including methotrexate, salazopyrine, leflunomide, and hydoxychloroquine, and 
tumor necrosis factor alpha (TNFα) inhibitors, have shown varying efficacy in patients 
with chronic disease following CHIKV infection (48). Additionally, long-term and 
combinatorial drug treatments for severe or persistent arthritogenic alphavirus infections 
can lead to adverse side effects such as gastrointestinal bleeding and bone deterioration in 
affected patients (15, 41, 42). 
Animal models of arthritogenic alphavirus-induced disease 
 To better understand the mechanisms of arthritogenic alphavirus pathogenesis, 
several animal models were generated to study the effects of infection in the laboratory. 
Intracranial infections of neonatal mice were used to study mortality and brain pathology 
following CHIKV and Semliki Forest virus (SFV) infections, while intranasal infections 
of CHIKV were used to study the effects of localized histological damage and viremia in 
mice (49). Some mouse models of SINV pathogenesis aimed to study the arthritic effect 
of the virus, although most SINV studies utilize the encephalitic model to study the 
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effects of SINV infection on neurological pathogenesis (50). More common models to 
study viral pathogenesis include subcutaneous infections into the footpads of C57BL/6 
mice to study RRV- and CHIKV-induced inflammation and tissue damage (51-54).  
 The mouse model of RRV pathogenesis utilized by Morrison and colleagues was 
the model used in the studies described in this work (53). This model of alphavirus-
induced arthritis/myositis involves a subcutaneous infection of 1000 PFU of RR64, an 
infectious clone of the T48 mouse-adapted strain of RRV, into the left-rear footpad of a 
twenty-four day old C57BL/6 mouse (53, 55). Over the course of infection, RRV-
infected mice show transient weight loss and develop disease characterized by hind limb 
weakness and altered gait (depicted in Figure 1.3, which is modified from Morrison and 
colleagues)(53). The clinical disease in these mice peaks in severity between 7-10 days 
post-infection, after which mice recover their hind limb function and are 
indistinguishable from mock-infected animals by 30 days post-infection.  
The disease induced by this RRV model can be further segregated into three 
distinct phases by histologically examining the skeletal muscle of RRV-infected animals 
over the course of infection because skeletal muscle is a target tissue for replication and 
pathology during infection (Figure 1.3) (53). The first phase of infection between 3-5 
days post-infection is the initiation/recruitment phase, during which time the initial 
recruitment of inflammatory cells into the tissue is visible, but the skeletal muscle fibers 
remain intact. The second phase of the disease is the tissue destruction phase, wherein 
there is substantial inflammatory infiltration and destruction of the skeletal muscle tissue. 
The inflammatory infiltrate is primarily monocytic, consisting mainly of monocytes, 
macrophages, and NK cells (53). The final phase of the disease is the resolution/repair 
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phase, wherein the inflammation resolves, and the muscle fibers repair. Notably, peak 
viral replication in the tissues occurs between 24-48 hours post-infection, suggesting that 
the disease correlates with inflammatory infiltration and not with viral replication (53). 
Additionally, numerous studies using the RRV mouse model have demonstrated the roles 
of innate immune components, including macrophages and complement, in mediating 
RRV-induced disease (51, 56-60). 
 Several treatment therapies and vaccine approaches are efficacious in animal 
models. Because macrophages are critical mediators of RRV-induced disease, some 
therapies focused on targeting this cellular population to ameliorate the disease (51, 56, 
57). Treatment of RRV-infected mice with bindarit, an inhibitor of monocyte chemotactic 
protein synthesis, resulted in significantly reduced tissue inflammation and damage 
compared to untreated mice (61). Additionally, a recent study showed complete 
protection from CHIKV challenge in mice immunized with a recombinant adenoviral 
vaccine, while another report demonstrated that a synthetic DNA vaccine protected mice 
and non-human primates from CHIKV-induced disease and elicited protective 
neutralizing antibody responses (62, 63). Mouse models of arthritogenic alphavirus-
induced disease provide important insights into the pathogenesis of Old World alphavirus 
infection and remain important tools for testing and discovering potential therapeutics for 
the associated diseases.   
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1.2 Toll-like receptor signaling 
 
Overview of toll-like receptors 
 Toll-like receptors (TLRs) are innate immune receptors that recognize conserved 
microbial patterns on the surface of pathogens such as viruses, fungi, parasites, and 
bacteria (64). TLRs are a class of pattern recognition receptors (PRRs), which are 
classified as such because they recognize specific pathogen-associated molecular patterns 
(PAMPs) that enable the receptor to identify the microbe as foreign and initiate an 
immune response. Other PRRs include the RIG-I-like receptors (RLRs) and Nod-like 
receptors (NLRs), and these PRRs signal exclusively from the cytosol. PRRs are 
expressed on a variety of immune cells, including phagocytic macrophages and dendritic 
cells (DCs), which use these receptors as a first line of defense against invading 
pathogens (65).  
 The basic structure of TLRs consists of a leucine-rich repeat extracellular domain, 
a membrane-spanning region and an intracellular region containing a Toll/interleukin-1 
receptor (TIR) domain (66). The binding of the horseshoe-shaped extracellular domains 
of TLRs by their specific PAMP-containing ligands induces a conformational change in 
the receptors and the accompanying dimerization of their extracellular domains. 
Interactions between the TIR domains of the intracellular regions of the TLRs are then 
believed to recruit specific TIR domain-containing adaptors to the activated receptors. It 
is postulated that activated TLRs may undergo higher order clustering with other TLRs, 
which would presumably allow for more efficient downstream signaling and activation 
(67, 68). X-ray structures reveal the TLR extracellular and intracellular domains of the 
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receptors in their monomeric forms, although multimeric and clustered forms of TLRs in 
their native transmembrane conformation are not available (66). 
 Upon recognition of a PAMP via receptor complex engagement, TLRs signal to 
their downstream adaptor molecules to activate a downstream signaling cascade that will 
lead to the appropriate immune response to the invading pathogen (64). The TLR-
induced signaling cascade leads to the activation of specific transcription factors, which 
can then induce the expression of various genes, such as pro-inflammatory cytokines, 
type I IFN, and IFN-stimulated genes (ISGs) (65). An overview of TLR signaling is 
depicted in Figure 1.4, which was adapted from Kawai and Akira with permission (69). 
 TLR signaling is modulated by the specificity of the TLR ligands and by the 
cellular localization of the receptors, which can affect ligand accessibility and 
downstream signal transduction. Based on these specific criteria, TLRs can be segregated 
into two groups: group A consists of TLRs 1, 2, 4, 5, 6 and 11, while group B consists of 
TLRs 3, 7, 8 and 9 (64). Group A TLRs are primarily localized to the plasma membrane 
except for TLR4, which can also be localized to endosomal compartments. Group B 
TLRs are localized to intracellular vesicles such as endosomes, lysosomes, 
endolysosomes, and the ER. With regards to PAMP sensing, Group A TLRs recognize a 
range of lipids and other microbial membrane components, while Group B TLRs 
recognize nucleic acids. This section will provide more in-depth background on TLR4 
and TLR7 because of their relevance to the studies discussed in this work. A description 
of the known human and murine TLRs, along with their ligands and adaptors, was 
adapted with permission from Li et al. and can be found in Table 1.2 (70-74).  
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 TLR4, which recognizes bacterial lipopolysaccharide (LPS), fungal mannans, and 
other microbial components, the chemotherapeutic drug, Taxol, and several endogenous 
molecules, is localized to both the cellular plasma membrane and to endocytic vesicles 
(64, 75-77). At the plasma membrane, TLR4, in complex with MD-2, signals through the 
adaptor molecule myeloid differentiation primary response gene 88 (Myd88), as well as 
the adaptor Mal/ TIR-domain-containing adaptor protein (TIRAP), within the Myd88-
dependent pathway. However, TLR4 also signals through a Myd88-independent pathway 
in endocytic vesicles, and this pathway recruits the adaptor molecules, TRIF-related 
adaptor molecule (TRAM) and TIR-containing-adaptor inducing interferon-b 
(TRIF)/TIR-domain-containing adaptor molecule 1 (TICAM-1). The Myd88-dependent 
TLR4 pathway leads to the activation of nuclear factor kappa B (NF-κB) through the 
phosphorylation and release of its inhibitory factor, IκB, by IκB kinases (IKKs) (78). The 
liberated NF-κB can then translocate into the nucleus and initiate pro-inflammatory 
cytokine gene expression. The TRAM/TRIF-dependent TLR4 pathway leads to NF-κB 
activation and interferon regulatory factor (IRF)3 serine phosphorylation, after which 
both transcription factors can transverse the nucleus to bind their respective promoters 
and commence gene transcription (64, 79). The activation of NF-κB and IRF3 signaling 
pathways lead to pro-inflammatory cytokine and type I IFN induction, respectively (65). 
TLR4 is expressed on a variety of immune cells, including macrophages, DCs, 
neutrophils, eosinophils, mast cells, B and T lymphocytes, and can be induced in a 
variety of non-professional tissues (75, 80-84). 
 TLR7, which is located on the X chromosome, is found exclusively within 
intracellular compartments and interacts with the membrane protein UNC93B to facilitate 
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signaling (64, 85). TLR7 recognizes viral ssRNA and synthetic ligands such as the 
imidazoquinoline derivatives, imiquimod and R848/resiquimod (86). Recognition of 
TLR7-specific PAMPs leads to the activation of Myd88-dependent signaling pathways, 
resulting in IRF7 and NF-κB activation. Serine phosphorylation of IRF7 leads to its 
translocation into the nucleus wherein it can bind to IFN-α and -β gene promoters and 
initiate the expression of Type I IFN genes, while NF-κB activation initiates pro-
inflammatory cytokine induction (64, 79). Plasmacytoid DCs (pDCs) preferentially 
express high levels of TLR7 and secrete type I IFN, particularly IFN-α, following TLR7 
activation (87). However, TLR7 signaling plays important and distinct roles in other 
immune cells such as myeloid DCs, eosinophils, macrophages, and B and T lymphocytes 
(75, 80, 82, 83).  
Toll-like receptor signaling during viral infection 
 The role of toll-like receptors in antiviral immunity is well-documented and 
established in the literature (88). One of the most important roles of TLRs during viral 
infection is to induce type I IFNs and other pro-inflammatory cytokines to stimulate an 
antiviral response in the host. Stimulation of TRIF-dependent signaling cascades via 
TLR3 or TLR4 activation lead to IRF3 phosphorylation and early IFN-β production 
during viral infection (79). Myd88-dependent TLR signaling leads to type I IFN 
production via IRFs and leads to pro-inflammatory cytokine production via NF-κB (65). 
One of the earliest producers of type I IFN during viral infection are pDCs, which express 
high levels of TLRs 7 and 9 and mediate IFN production through these TLR sensing 
pathways (87, 88).  
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Intracellular nucleic acid-sensing TLRs, including TLRs 3, 9 and 7, may 
recognize viral nucleic acids through multiple mechanisms during infection (65). The 
first mechanism through which intracellular TLRs may recognize viral nucleic acids is 
through direct recognition following endocytosis of the virion. Because of the highly 
acidic and enzymatic environment within endocytic compartments (such as lysosomes), 
the endocytosed viral particle may become damaged within the endosome, which could 
lead to the release of nucleic acid into the vesicle and result in TLR engagement. An 
alternative mechanism of intracellular TLR activation could be through the uptake of 
virally infected cells by phagocytes. Nucleic acid-containing viral capsids from apoptotic 
cells may be trafficked to lysosomal compartments in the phagocytes wherein the capsids 
can be degraded to release the viral RNA or DNA for TLR activation (65).  
TLR3 and TLR9, which recognize double-stranded RNA (dsRNA) and DNA 
respectively, have been reported to recognize a variety of RNA and DNA viruses (88). 
Activation of TLR7 signaling has been observed during infections with multiple RNA 
viruses, including influenza virus, West Nile virus, HIV, Friend virus, vesicular stomatitis 
virus, yellow fever virus, lymphocytic choriomeningitis virus, and murine pneumonia 
virus (89-95). In addition to mediating antiviral immunity via type I IFN induction, TLR7 
has recently been shown to play an important role in adaptive immune responses to viral 
infection (88). Indirect effects of TLR7 signaling via type I IFN and cytokine production 
influences T cell differentiation, and TLR7 expression in B cells is critical for generating 
protective antibody responses to multiple viral infections (80, 82, 96). Moreover, the 
TLR7 agonist imiquimod, which induces IFN-α and pro-inflammatory cytokine 
production through TLR7 signaling, has shown efficacy in the treatment of human 
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papillomavirus-induced genital warts by enhancing antigen presentation and promoting 
antigen-specific T helper type 1 (Th1) cell-mediated immune responses (97). 
The mechanisms through which plasma membrane-expressed TLRs are activated 
during viral infection are not well defined. Evidence suggests that certain viral proteins, 
including viral envelope glycoproteins, can serve as TLR ligands during infection (88). 
TLR2 has been implicated to recognize a variety of viral proteins, and TLR4 has been 
implicated to recognize mouse mammary tumor virus (MMTV) and respiratory syncytial 
virus (RSV) envelope proteins (88, 98-102). MMTV-mediated activation of TLR4 leads 
to IL-10 production, which promotes an anti-inflammatory response during infection and 
prevents viral clearance (100). TLR4 signaling also plays protective and pathologic roles 
in a variety of viral infections, including KSHV, hepatitis C virus, influenza virus, 
hantaan virus, and Chandipura virus, although the mechanism of TLR4 recognition of 
these viruses has not been reported (103-108). TLR4-mediated cytokine induction 
mediates inflammatory cell infiltration and activation at the sites of infection, and TLR4 
agonists have shown efficacy in promoting protective antibody responses to viral 
vaccines (64, 96). 
The role of toll-like receptors in autoimmunity and arthritis 
 In addition to mediating immune responses to microbial pathogens, TLRs 
recognize and become activated in response to a range of host molecules, which can lead 
to the development of autoimmune disorders (109). The expression of TLRs 2, 4, and 9 
correlate with the development of type I diabetes mellitus, while multiple studies 
demonstrate that TLR7 and TLR9 mediate systemic lupus erythematosus through the 
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production of autoantibodies (109, 110). Moreover, the expression of multiple TLRs is 
elevated in rheumatoid arthritis patients (109). 
Because of its ubiquitous expression in immune cells and non-professional tissues 
and its ability to recognize a wide range of ligands, TLR4 is implicated in the 
development of multiple autoimmune conditions (75, 109). In addition to recognizing 
bacterial LPS and other PAMPs, TLR4 has been shown to recognize several endogenous 
molecules that can trigger immune responses in the presence or absence of infection (75). 
TLR4 recognizes several damage-associated molecular patterns (DAMPs) such as heat-
shock proteins (HSPs), which are produced following exposure to various environmental 
stress conditions (111-113). Heparan sulfate proteoglycans, hyaluronic acid 
oligosaccharides, fibrinogen, oxidized lipoproteins, and saturated fatty acids also induce 
TLR4 activation in mice and macrophages (114-118).  
Besides its potential roles in diabetes, inflammatory bowel disease, multiple 
sclerosis, and cancer, multiple studies demonstrate that TLR4 signaling plays a 
pathologic role in human and mouse models of arthritis (109, 119-127). The predominant 
mechanism of TLR4-mediated disease in arthritis and other autoimmune disorders is 
through its role in exacerbating local and systemic inflammation, which has led to the 
development of several TLR4 antagonists that are currently undergoing clinical trial 
evaluation (128). Additionally, TLR4 is stimulated by the myeloid inflammatory 
calgranulins, s100A8 and s100A9, which can promote autoreactive CD8+ T cell activity 
and are expressed in a TLR4-dependent manner in osteoarthritis patients and juvenile 
idiopathic arthritis (129-133). Moreover, the expression of TLRs 2, 3, 4 and 7 were 
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enhanced in the synovial fluid of rheumatoid arthritis patients, suggesting that multiple 
TLRs may function in the development of arthritic diseases (109, 134). 
 
1.3 Host response to alphavirus infection 
 
Type I/II IFN responses to infection 
 Several immune pathways are implicated in the host response to alphavirus 
infection. Because of their critical roles in antiviral immunity, the type I and II IFN 
pathways are widely studied in the context of alphaviruses (135-139). The induction of 
type I IFN is critical for early control of viral replication following Old World and New 
World alphavirus infection in mice, while type I (IFN-α and –β) and type II (IFN-γ) IFN 
responses influence adaptive immune responses to infection (135). Type I IFN receptor 
(IFN-α/βR)-deficient mice, which are unable to respond to type I IFN, rapidly succumb to 
infection with mutant SINV, VEEV, and SFV strains that are avirulent in wild-type (WT) 
mice (137, 138, 140). Moreover, IFN-α/βR-deficient mice show an inability to control 
viremia following CHIKV infection and also succumb rapidly to virus-induced disease 
(139, 141). Treatment with IFN-α or IFN-γ also demonstrates potent antiviral activity 
against alphavirus-induced CPE in cell culture, and antibody-mediated inhibition of type 
I IFN results in enhanced VEEV replication in macrophages (142, 143). Signal transducer 
and activator of transcription 1 (STAT1)-deficient mice, which are unable to mount 
positive feedback amplification of type I IFN, show diminished type I IFN responses and 
enhanced lethality following alphavirus infection (141, 144, 145). Regarding the adaptive 
arm of the immune response, type I IFN is required for efficient lymphocyte activation 
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during SFV infection, and the induction of type I IFN is dependent on viral replication 
(140, 146). Furthermore, IFN-γ-deficient mice show increased susceptibility to SFV-
induced mortality and succumb to infection between 7-10 days post-infection, suggesting 
that IFN-γ is necessary for stimulating protective adaptive immune responses to 
alphavirus infection (147). 
Because IRFs mediate type I IFN and inflammatory gene induction, IRF-
dependent gene transcription is essential for protective antiviral responses during 
alphavirus infection. Both IRF3 and IRF7 are required for efficient type I IFN signaling 
during viral infection, with IRF3 responsible for initial type I IFN responses and IRF7 
required for late IFN-α/β transcription (148). IFN induction via IRF3 and IRF7 activation 
pathways are required for protection against CHIV-induced mortality in mice, and mice 
deficient in both IRF3 and IRF7 succumb to fatal CHIKV infection despite robust IFN-γ 
responses (149, 150). IFN-α induction is mediated by IRF7 following neurovirulent 
SINV infection in microglial cultures (149, 151). Furthermore, protection from WEEV 
cytopathology is dependent on IRF3-mediated type I IFN responses in mice. (152). Other 
IRFs such as IRF-1 and IRF-2 may also be important in protection from alphavirus-
induced disease because mice deficient in these IRFs showed increased susceptibility to 
VEEV replication and virus-induced pathology (143).  
Alphavirus infection induces the expression of an array of antiviral genes, 
including interferon-stimulated genes (ISGs) (135, 142, 153-156). ISG15 is critical for 
controlling SINV and CHIKV infections, and virus-induced expression of ISG15 protects 
IFN-α/βR-deficient mice from lethal SINV infection (157-159) Furthermore, mice 
lacking RSAD2, which encodes the ISG viperin, showed increased viremia and virus-
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induced pathology during CHIKV infection compared to WT mice (160). Expression of 
the human MxA protein confers resistance to SFV replication in vitro, and bone marrow 
stromal antigen 2 (BST-2) reportedly functions to antagonize CHIKV infection by 
retaining progeny viral particles on the surface of the host cell (161, 162). Additionally, 
the ISG PARP inhibited the replication of multiple alphaviruses, including VEEV, SINV, 
and CHIKV, and expression of the IFN-induced 2’, 5’-Oligoadenylate Synthetase 
(OAS)3 inhibited CHIKV replication in cell culture (163, 164). Moreover, data suggests 
that the zinc finger antiviral protein (ZAP), which attenuates SINV virulence in neonatal 
mice, synergizes with multiple ISGs to mediate alphavirus inhibition (156, 165). 
Because of the important roles of IFN in controlling viral replication and 
modulating adaptive immune responses during alphavirus infection, Old World and New 
World alphaviruses have developed mechanisms of IFN inhibition to allow for the 
establishment and dissemination of infection (31, 166). Old World alphaviruses, 
including SFV, CHIK, and SINV, utilize mechanisms of transcriptional and translational 
shutoff to block IFN induction during infection (31-33). The NSP2 proteins of CHIKV, 
SFV, and SINV induce transcriptional shutoff by mediating ubiquitination of Rbp1, a 
catalytic subunit of the RNA polymerase II complex (167). Alphaviruses also mediate 
shutoff-independent mechanisms of IFN inhibition by blocking STAT phosphorylation, 
thereby preventing amplification of type I and II IFN responses (29, 32, 135, 168, 169). 
Moreover, alphaviruses may target the downstream effects of IFN by inhibiting ISGs. 
The NSP1 of CHIKV has been shown to actively antagonize the antiviral function of 
BST-2 by downregulating BST-2 expression, and there may be other ISGs targeted by 
alphaviruses as well (161).  
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Immunopathology associated with alphavirus infection 
 The immune-mediated pathology associated with alphavirus infection is well-
characterized (15, 136, 170). Arthritogenic alphaviruses such as RRV and CHIKV induce 
severe myositis and arthritis in humans that correlate with host inflammatory responses 
and persist in the absence of active viral replication (15, 46). Gene profiling reveals that 
CHIKV-induced arthritis generates a similar gene expression signature to rheumatoid 
arthritis and collagen-induced arthritis, indicating that the host inflammatory pathways 
induced by these arthritides overlap (171). Additionally, the host complement pathway 
promotes RRV-induced morbidity and tissue damage in mice, although complement 
reportedly functions to limit neuropathology during encephalitic alphavirus infection (53, 
59, 60, 172-174). Evidence also suggests that macrophages contribute to arthritogenic 
alphavirus pathogenesis (15). Depletion of macrophages or macrophage-dependent 
factors results in significantly reduced inflammation and tissue destruction following 
RRV infection, and mice treated with Bindarit, an inhibitor of monocyte chemotactic 
protein-1 (MCP-1), show significantly reduced disease following RRV or CHIKV 
infection (51, 57, 61, 175, 176). Alphavirus-associated immunopathology is not limited to 
arthritogenic alphaviruses, however, because depletion of NK cells resulted in a delayed 
mean time to death following SFV infection, and NK cell-induced immunopathology is 
mediated by the granule-exocytosis and Fas cytotoxic pathways (147).  
The role of pattern-recognition receptors during infection 
 PRRs, which recognize and respond to viral PAMPs through the induction of IFN 
and pro-inflammatory cytokines, also mediate antiviral signaling during alphavirus 
infection. The RLR helicases, RIG-I and MDA5, are implicated in mediating antiviral 
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responses to alphavirus infection (165, 177, 178). MDA-deficient macrophages show 
slightly impaired IFN-α production following SINV infection, and both RIG-I and 
MDA5 can mediate a synergistic effect with the ISG ZAP to induce antiviral activity 
against SINV in vitro (165, 179). However, because RIG-I-deficient mice are embryonic 
lethal or die shortly after birth, it is unclear whether the antiviral activity of RIG-I during 
alphavirus infection is biologically relevant in vivo (180). IPS-1, which is an adaptor for 
MDA5 and RIG-I, mediates IRF-dependent type I IFN and antiviral gene transcription 
during CHIKV infection (150, 181). Additionally, mice deficient in IPS-1 succumb to 
avirulent SINV infection, and CHIKV-infected IPS-1-deficient mice show increased 
viremia and increased foot swelling compared to WT mice (150, 182). Another 
cytoplasmic RNA sensor, the double-stranded RNA-binding protein kinase R (PKR), 
induces type I IFN and regulates IFN-α/β mRNA stability during SFV infection (183). 
Moreover, SINV infection induces translational shutoff via PKR-dependent and PKR-
independent mechanism in vitro, suggesting a role for multiple PRRs in the host response 
to alphavirus infection (184). 
 There is also evidence that host c-type lectin receptors (CLRs), which recognize 
viral glycans, also regulate the host response to alphavirus infection. Alphavirus 
glycoproteins, E1 and E2, are N-linked glycosylated, and the viral glycosylation patterns 
are dependent on the species within which the virus is propagated (1). Type I IFN 
expression during alphavirus infection is modulated by differential glycosylation patterns 
between mosquito- and mammalian-derived viruses, and mutations in SINV N-linked 
glycans results in altered viral infectivity and virulence in mice (40, 185, 186). 
Additionally, human monocytic THP-1 cells become permissive to SINV replication 
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when they express the CLRs DC-SIGN or L-SIGN, suggesting that DC-SIGN or L-SIGN 
may facilitate SINV entry into host cells (187). The complement-dependent activity of 
the soluble CLR, mannose binding lectin (MBL), promotes RRV-induced disease in mice 
and correlates with severe RRV-induced disease in humans (60). Furthermore, mice 
deficient in the dendritic cell immune receptor (DCIR), a CLR that negatively regulates 
the host inflammatory response, showed increased morbidity and tissue damage 
following CHIKV infection, suggesting that DCIR plays a protective role in regulating 
the inflammatory response to CHIKV (188).  
There is limited data regarding the role of TLRs in alphavirus infection. The TLR 
adaptor, Myd88, protects CHIKV-infected mice from significant viral dissemination 
during infection (141). Although Myd88-deficient mice do not show enhanced disease as 
indicated by foot swelling during CHIKV infection, TRIF-deficient mice show increased 
serum viremia and enhanced foot swelling compared to WT mice, suggesting that a 
TRIF-dependent, Myd88-independent TLR pathway may contribute to protection from 
severe CHIKV-induced disease (150). Treating cells with the TLR3 agonist, Poly (I:C), 
inhibits CHIKV replication through TLR3-dependent antiviral responses (189). Although 
TLR3- and Myd88-deficient mice show similar phenotypes to WT mice following 
neurovirulent SINV infection, TRIF-deficient mice show increased susceptibility to 
SINV-induced mortality, suggesting that perhaps TRIF-dependent TLR signaling may 
contribute to protection from SINV-induced neurologic disease (144, 151, 182).  
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1.4 Dissertation objectives 
 
Despite significant contributions to the understanding of the host response to 
alphavirus infection, many of the signaling pathways and mechanisms underlying 
alphavirus pathogenesis remain poorly defined. As mentioned in the previous discussion, 
IRF-mediated IFN induction is required for protection from alphavirus-induced disease, 
and some studies have reported that IPS-1 contributes to IRF activation. However, it is 
unclear which PRRs are required for effective antiviral responses during alphavirus 
infection in vivo, and the mechanisms by which PRRs mediate inflammatory responses to 
alphavirus infection have not been reported. In particular, the role of TLRs during 
alphavirus infection is largely undefined. Furthermore, the host pathways that contribute 
to immune-mediated pathology during arthritogenic alphavirus infection are poorly 
understood. Although macrophages and complement activation mediate RRV-induced 
disease, it is unclear whether other cell types or pathways contribute to arthritogenic 
alphavirus pathogenesis. 
Our primary goal in these studies was to further elucidate the host pathways 
underlying arthritogenic alphavirus infection. Specifically, we aimed to 1) determine 
whether TLRs were important host factors in the response to arthritogenic alphavirus 
infection and if so, 2) determine the mechanism(s) of TLR-mediated protection or 
enhancement of arthritogenic alphavirus-induced disease. We initially tested whether the 
central TLR signaling adaptor, Myd88, played any role in the host response to RRV 
infection and found that Myd88 mediated protection from severe RRV-induced morbidity 
and mortality. We also found that Myd88-dependent protection from severe RRV-
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induced disease was dependent on TLR7, and we demonstrated that Myd88-dependent 
TLR7 deficiency resulted in a failure to control viral replication late during infection that 
correlated with a loss in protective virus-specific antibody responses. Moreover, we 
found that mice deficient in TLR7 or Myd88 showed antibody- and complement-
dependent disease in both skeletal and cardiac muscle tissue. Because of its demonstrated 
roles in viral infections and arthritic diseases, we also tested whether TLR4 contributed to 
arthritogenic alphavirus-induced disease in a mouse model of RRV arthritis/myositis and 
found that TLR4 promoted RRV-induced morbidity and tissue damage in a complement-
dependent manner. Additionally, we demonstrated that complement-dependent 
macrophage activation during RRV infection was dependent on TLR4 expression. Taken 
together, these findings demonstrate that TLRs contribute to protection from and 
enhancement of arthritogenic alphavirus infection. The aims addressed herein are: 
 
Aim 1: To determine the cell types involved in mediating TLR-induced pathogenesis 
during RRV infection. 
 
Aim 2: To determine whether TLRs and complement activate the same signaling 
pathways to induce pathogenesis during RRV infection. 
 
Aim 3: To determine the signaling pathways upstream and downstream of TLR7 
activation involved in protection from RRV-induced disease. 
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Table 1.1: Alphavirus classification and epidemiology 
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Table 1.2: TLR overview   
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Figure 1.1 
         
Figure 1.1: Alphavirus transmission cycles 
Enzootic and epidemic/endemic transmission cycles of alphaviruses.  
 
 
 
 
 
 
 
Culex spp. 
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Figure 1.2 
 
 
Figure 1.2: Alphavirus genome 
Simplified schematic of the alphavirus genome, with major protein functions and 
locations of N-linked glycosylation sites indicated. 
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Figure 1.3 
 
 
Figure 1.3: Mouse model of RRV infection 
In this model of alphavirus-induced arthritis/myositis, 24 day-old C57BL/6 mice are 
subcutaneously infected in the left-rear footpad with 10
3
 PFU of RR64, the molecular 
clone of RRV. Over the course of infection, mice show transient weight loss (not 
pictured) and develop disease signs that are characterized by hind limb weakness. Peak 
disease, which occurs between 10 and 12 days post-infection, correlates with skeletal 
muscle damage and inflammation. 
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Figure 1.4 
 
 
 
Figure 1.4: Overview of TLR signaling 
TLRs initiate signal transduction in various cell types to mediate immune responses to 
infections. Upon stimulation by specific pathogenic (or endogenous) ligands, TLRs 
recruit their respective downstream adaptor(s) to activate signaling pathways that lead to 
type I IFN and inflammatory cytokine induction.   
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CHAPTER TWO: 
MYD88-DEPENDENT TLR7 SIGNALING MEDIATES PROTECTION FROM 
SEVERE ROSS RIVER VIRUS-INDUCED DISEASE IN MICE
† 
 
2.1 Overview 
 
Arthralgia-associated alphaviruses, including chikungunya virus (CHIKV) and 
Ross River virus (RRV), pose significant public health threats because they cause 
explosive outbreaks of debilitating arthralgia and myalgia in human populations. 
Although the host inflammatory response is known to contribute to the pathogenesis of 
alphavirus-induced arthritis and myositis, the role that toll-like receptors (TLRs), which 
are major regulators of host antiviral and inflammatory responses, play in the 
pathogenesis of alphavirus-induced arthritis and myositis has not been extensively 
studied. Using a mouse model of RRV-induced myositis/arthritis, we found that myeloid 
differentiation primary response gene 88 (Myd88)-dependent TLR7 signaling is involved 
in protection from severe Ross River Virus (RRV)-associated disease. Infections of 
Myd88- and TLR7-deficient mouse strains with RRV revealed that both Myd88 and 
TLR7 significantly contributed to protection from RRV-induced mortality, and both 
mouse strains exhibited more severe tissue damage than wild-type (WT) mice following 
RRV infection. Additionally, while viral loads were unchanged in either knockout when 
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compared to WT mice at early times post-infection, both Myd88 and TLR7 knockout 
mice exhibited higher viral loads than WT mice at late times post-infection. Furthermore, 
while high levels of RRV-specific antibody were produced in TLR7-deficient mice, this 
antibody had very little neutralizing activity and had lower affinity compared to WT 
antibody. Additionally, TLR7- and Myd88-deficient mice showed defects in germinal 
center activity, and the passive transfer of antisera from TLR7-deficient mice failed to 
protect WT mice from RRV-induced disease, suggesting that TLR7-dependent signaling 
is critical for the development of protective antibody responses against RRV. 
 
2.2 Introduction 
 
Mosquito-transmitted alphaviruses cause a variety of disease states in animals and 
humans, ranging from joint and muscle pain to severe neuropathology and encephalitis 
(4, 5, 45). Because of the wide distribution of their viral vectors and their ability to cause 
explosive outbreaks of debilitating arthralgia and myalgia, arthralgia-associated viruses 
such as chikungunya virus (CHIKV) and Ross River virus (RRV) are considered to be 
significant emerging disease threats (42, 190-192). Though rarely fatal, alphavirus-
induced arthritis can be quite debilitating and can progress to chronic disease in a 
significant subset of individuals, thereby significantly affecting the patients’ quality of 
life and placing substantial burdens on health care systems (16). 
Several studies have demonstrated that immune pathology contributes to 
alphavirus-induced arthritis and myositis (51, 56-59, 175). Mouse models of arthritogenic 
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alphavirus infection have implicated inflammatory macrophages and complement in the 
development of alphavirus-induced disease (51, 53, 56, 57, 59, 175, 193). However, the 
signaling pathways underlying alphavirus pathogenesis remain poorly understood, and 
further characterization of the pathways contributing to alphavirus-induced arthritis and 
myositis may lead to the development of more effective antiviral therapies to treat 
affected individuals (192). 
Toll-like receptors (TLRs) are pattern-recognition receptors that recognize 
conserved microbial patterns on pathogens, including bacteria, fungi and viruses (64). 
Following TLR engagement and stimulation by invading microbes, specific adaptor 
molecules interact with the activated TLRs and then initiate downstream signaling 
cascades to promote innate immune responses and target the associated infection (194). 
Although TLRs have been found to play a role in many virally-induced diseases, usually 
functioning in a protective capacity, and certain TLRs, including TLRs 1, 2, 3, 7, 8 and 9, 
and the TLR adaptor molecule myeloid differentiation primary response gene 88 
(Myd88), have been found to be upregulated during alphavirus infection (144, 195, 196), 
the importance of TLRs in the pathogenesis of alphavirus-induced arthritis/myositis has 
not been elucidated. 
To determine whether TLRs influence alphavirus pathogenesis, we evaluated the 
role of Myd88 in a mouse model of RRV-induced arthritis/myositis. Because Myd88 is 
essential for signaling by all TLRs except for TLR3 and partial TLR4 signaling, we chose 
first to focus our studies on Myd88 to determine whether RRV-induced disease is 
impacted by the absence of this central TLR signaling molecule (194, 197-199). Here we 
report that mice deficient in Myd88 developed more severe disease and RRV-induced 
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mortality compared to RRV-infected wild-type C57BL/6J (WT) mice, and that TLR7-
deficient animals exhibited an almost identical phenotype to the Myd88-deficient mice 
during RRV infection. Moreover, mice deficient in TLR7 produced less neutralizing 
antibodies following RRV infection when compared with WT animals, suggesting that 
Myd88-dependent TLR7 signaling is required for the control of RRV replication and for 
protection from severe RRV-induced disease. 
 
2.3 Materials and Methods 
 
Virus stocks and cells. Viral stocks of the mouse-virulent T48 strain of Ross River Virus 
(RRV) were generated
 
from the full-length T48 cDNA clone (generously provided by 
Richard Kuhn,
 
Purdue University) as previously described (55). Viral titrations were 
determined by plaque assay on Vero cells as described below.
 
Fresh and confluent Vero 
cell monolayer, grown in DMEM/F12 (Gibco) with 10% Hyclone FBS, 1% non-essential 
amino acids, 1% Pen/Strep, 2.5% NaHCO3 (Gibco) and 1% L-glutamine, were used for 
all plaque assay and PRNT assay experiments. 
Mouse experiments. C57BL/6J wild-type (WT), TLR7-deficient (TLR7
–/–
), and Myd88-
deficient (Myd88
–/–
) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) 
and bred in-house. TLR7
–/–
 and Myd88
–/–
 mice were both maintained on a C57BL/6 
background. Animal
 
husbandry and experiments were performed in accordance with
 
all 
UNC-CH Institutional Animal Care and Use Committee guidelines.
 
All mouse studies 
were performed in
 
a biosafety level 3 laboratory. Twenty-four day old mice were
 
used for 
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all in vivo studies. Mice were anesthetized
 
with isoflurane (Halocarbon Laboratories) 
prior to subcutaneous inoculation in the left
 
rear footpad with 10
3
 PFU of virus in 
phosphate-buffered
 
saline (PBS) diluent in a 10 µl volume.
 
Mock-infected animals were 
inoculated with PBS diluent alone. Mice were weighed and monitored
 
daily for clinical 
disease signs. Disease scores
 
were determined by assessing grip strength, hind-limb 
weakness
 
and altered gait as described previously (53). Briefly, mice were scored on a 
scale from 0 to 5, wherein 0 indicated no disease signs, 1-2 indicated ruffled fur and mild 
hind limb weakness, 3-4 indicated moderate hind limb weakness and altered gait, 5 
indicated severe hind limb weakness and dragging of hind limbs, and 6 indicated that the 
mice were moribund and thus unable to consume adequate amounts of food and water, 
thus meeting euthanasia criteria. 
Viral titers. To determine viral titers in RRV-infected murine tissues, mice were 
anesthetized and sacrificed by exsanguination. Quadriceps tissues were excised and 
homogenized and serum was extracted prior to freezing at -80°C until viral titers were 
assessed. Viral tissues were thawed on ice and subsequently diluted in PBS diluent in 10-
fold dilutions. After dilution, 200 µl of infected tissue samples were pipetted into each 
well of 70% confluent Vero cells in duplicate for each dilution. The samples were 
incubated on the cells for 1 hour at 37°C in a CO2 incubator and gently agitated every 15 
minutes to ensure a uniform distribution of the inoculum on the cell monolayer. After 
incubation, the cells were overlayed with an agar overlay solution consisting of 50% of 
2.5% CMC (Sigma), 50% 2X Modified Eagles Media, 3% FBS, 1% Pen/Strep, 1% L-
glutamine and 1% 1M HEPES buffer (Mediatech), and incubated for 48-72 hours at 37°C 
in a CO2 incubator. Cells were then fixed with 4% Paraformaldehyde for 24 hours, 
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counterstained with a 0.25% Crystal Violet solution in water, and viral plaques were 
counted. 
Histological analysis. At 10 days post-infection, mice were sacrificed and perfused with 
4% paraformaldehyde, pH 7.3. Excised tissues were embedded
 
in paraffin, and 5-µm 
sections were prepared. To determine
 
the extent of inflammation and tissue pathology, 
tissues were
 
stained with hematoxylin and eosin (H & E) (53). Stained sections
 
were 
blinded and scored for overall inflammatory cell
 
infiltration and tissue damage as 
described (53). Both scoring systems utilized a 10-point scale where a score
 
of 0-3 
represents no to mild inflammation or damage, 4-6 represents moderate inflammation or 
damage, and 7-10 represents severe inflammation or damage.  For the analysis of 
germinal center formation, spleen tissue from WT and TLR7
-/-
 mice were stained with H 
& E, and stained sections were blinded and scored for the number of germinal centers 
(GCs) and the number of total follicles within the section. GCs were identified within 
each follicle by their characteristic staining pattern of a pale, circular region surrounded 
by a darker region containing the mantle and marginal zones.
 
Flow cytometry. Mice were inoculated as described above, sacrificed by exsanguination
 
at indicated times post-infection and perfused with 1X PBS.
 
Quadriceps muscles or 
spleens were dissected, minced, and incubated for
 
1.5-2 hours with vigorous shaking at 
37°C in digestion buffer (RPMI,
 
10% fetal bovine serum, 15 mM HEPES, 2.5 mg/ml 
collagenase A
 
[Worthington Biochemical Co.], 17 µg/ml DNase I [Roche]). Digested 
tissues were pelleted, resuspended in
 
HFA buffer (Hanks balanced salt solution [Gibco], 
1% fetal bovine serum, 0.1% sodium azide), passed
 
through a 70 µm cell strainer, and 
centrifuged
 
for 8 min at 1,000 rpm. Cells were resuspended in HFA buffer,
 
and viable cell 
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totals were determined by trypan blue exclusion.
 
Isolated cells were incubated with 
various antibodies, according to the associated staining panel, for 30 min to an hour at 
4°C in fluorescence-activated
 
cell sorter staining buffer (1x Hanks balanced salt solution,
 
1% fetal bovine serum, 2% normal rabbit serum). Cells were washed, fixed overnight
 
in 
2% paraformaldehyde and analyzed on a Cyan cytometer (Becton
 
Dickinson) using 
Summit software. Isolated splenocytes from mock-infected animals were prepared 
similarly and used for single-color staining controls. The lymphocyte staining panel 
included the following
 
antibodies: anti-NK1.1-phycoerythrin (PE) (eBioscience), anti-
CD3-fluorescein
 
isothiocyanate (FITC) (eBioscience), anti-B220-PE Texas Red (PETR) 
(Invitrogen), anti-LCA-PECy5 (eBioscience), anti-F4/80-PECy7 (eBioscience), anti-
CD4-pacific blue (PB) (Caltag Laboratories), anti-CD8-pacific orange (PO) (Invitrogen), 
anti-CD49b-allophycocyanin (APC) (eBioscience), and anti-GL7-Alexa88 (eBioscience). 
The monocyte staining panel included the following antibodies: anti-Ly6G-FITC (BD 
Pharmingen), anti-SigLecF-PE (BD Pharmingen), anti-CD11c-PETR (Invitrogen), anti-
LCA-PECy5 (eBioscience), anti-F4/80-PECy7 (eBioscience), anti-CD11b-eF450 
(eBioscience),
 
anti-MHC class II-APC (eBioscience), and anti-B220-eF780 
(eBioscience). 
The gating strategies were as follows:  For the inflammatory leukocytes, CD11c+, 
LCA+ viable cells were displayed on a histogram of Gr-1 plotted versus SigLecF. 
Neutrophils appear as a distinct Gr-1 high population and SigLecF+ cells appear on the 
other side of the diagonal. The SigLecF+ subpopulation is displayed on a histogram of 
CD11b versus CD11c, where eosinophils appear as a CD11b high, CD11c low group, 
while resident macrophages are CD11b low, CD11c high. With neutrophils and SigLecF 
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high groups gated out, the remaining CD11c positive cells are displayed on a plot of 
MHC class II versus B220. The B220 high, MHC class II low pDCs are gated out and the 
remaining cells are displayed on a plot of MHC class II versus CD11b; the MHC class II 
low cells are enumerated as monocyte-derived DCs (also referred to as TIP-DCs in some 
publications), and MHC class II high, CD11b hi cells are classified as inflammatory DCs 
(or CD11b high DCs). For lymphocyte populations, viable lymphocytes (selected by 
forward/side scatter characteristics) are plotted on a histogram of CD3 versus 
autofluorescence, and the CD3+ cells are further displayed on a plot of CD4 versus CD8.  
Lymphocytes that are both CD19+ and B220+ are counted as B cells and those that are 
both CD49b+ and NK1.1+ are counted as NK cells. 
Type I IFN (IFN-α/β) bioassay. IFN-α/β levels in cell culture supernatants were 
measured
 
by an IFN bioassay as described previously (40, 185). Briefly, L929 mouse
 
fibroblasts (ATCC CCL-1) were seeded into 96-well plates and
 grown in αMEM media. 
Samples were diluted 1:5 in αMEM media, acidified to a pH of 2.0 for 24 hours and then 
neutralized to pH 7.4. Samples were then subjected to UV light for 15 minutes to 
inactivate any remaining virus, followed by titration of the samples by two-fold serial 
dilutions across the seeded 96-well plate.
 
Twenty-four hours later, encephalomyocarditis 
virus was added
 
to each well at an MOI of 5. At 18 to 24 hpi, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium
 
bromide (MTT; Sigma) was added to the plate to 
assess the viability in each
 
well. The MTT product produced by viable cells was 
dissolved
 
in isopropanol containing 0.4% hydrochloric acid and quantified by absorbance 
readings
 
on a microplate reader at 570 nm. Each plate contained an IFN-β standard 
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(Chemicon or R&D Systems) that was used to determine
 
the number of international 
units of IFN-α/β per milliliter of the unknown samples. 
Plaque reduction neutralization test (PRNT) assay. Neutralizing antibody titers were 
determined by PRNT assay on Vero cell monolayers. Briefly, mice sera were heat-
inactivated at 56°C for 30 minutes in a water bath and then placed on ice. Identical 
volumes (200 µl) of two-fold mice sera dilutions (1:2) and wild-type RRV (10
3
 PFU 
virus/ml of PBS diluent) were mixed together and incubated at 37°C for 30 minutes in a 
water bath. After incubation, 200 µl of serum/virus sample mixture were pipetted into 
each well of 70% confluent Vero cells in duplicate for each dilution. The samples were 
incubated on the cells for 1 hour at 37°C in a CO2 incubator and gently agitated every 15 
minutes to ensure a uniform distribution of the inoculum on the cell monolayer. After 
incubation, the cells were overlayed with an agar overlay solution consisting of 50% of 
2.5% CMC (Sigma), 50% 2X Modified Eagles Media, 3% FBS, 1% Pen/Strep, 1% L-
glutamine and 1% 1M HEPES buffer (Mediatech), and incubated for 48-72 hours at 37°C 
in a CO2 incubator. Cells were then fixed with 4% Paraformaldehyde for 24 hours, 
counterstained with a 0.25% Crystal Violet solution in water, and viral plaques were 
counted. Neutralizing antibody titers are expressed as PRNT50, which is the reciprocal 
dilution wherein 50% of the total number of viral plaques in the virus/PBS diluent 
samples was reduced. 
Enzyme-linked immunosorbent assay (ELISA). RRV-specific antibody titers in sera of 
infected mice were determined by ELISA with inactivated RRV (1µg/ml) on high-
binding 96-well plates. The serum was first diluted 20-fold and then further diluted in 
two-fold serial dilutions. The ELISA antibody titer expressed is the estimated dilution 
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factor that gave an OD450 = 0.2 and is derived from nonlinear regression analysis of the 
serial dilution curve. Detection of bound antibody is obtained using an HRP-conjugated 
goat anti-mouse secondary antibody (Abcam, Cambridge, MA) and ABTS substrate 
(Invitrogen). 
Antibody Affinity ELISA. RRV-specific antibody titers in sera of WT and TLR7
-/-
 
infected mice were first determined by ELISA as described above. Inactivated RRV 
(1µg/ml) was then plated on high-binding 96-well plates for 12-24 hours, and sera was 
diluted in antibody diluent (PBS containing 0.05% Tween-20 and 10% Sigma Block) and 
then plated at a known dilution across the plate to obtain maximum antibody-antigen 
binding and then incubated at 4ºC for 2 hours. Following the sera incubation, increasing 
concentrations of sodium thiocyanate (NaSCN) were added to the plate to serially 
dissociate the antibody-antigen complexes, followed by incubation with a conjugated 
secondary IgG antibody and substrate incubation as described in the ELISA protocol 
above. Values were reported as the percent maximum total IgG binding at each NaSCN 
concentration. 
Passive serum transfer. Twenty-four day old WT and TLR7
-/-
 mice were 
subcutaneously infected in the left rear footpad with 10
3
 PFU of RRV and subsequently 
harvested at day 10 post-infection by exsanguination. Serum from each strain of infected 
mice was collected, pooled according to strain, and heat-inactivated at 56ºC for 1 hour. 
Twenty-four day old naïve WT mice were then inoculated with 50 µl of the heat-
inactivated WT or TLR7
-/-
 antisera. At one hour post-serum transfer, the mice were 
subcutaneously infected in the left rear footpad with 10
3
 PFU of RRV and monitored 
daily for weight loss and disease signs as described above. 
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Statistical analyses. Data were analyzed using Prism software (GraphPad Software, 
Inc.). Comparisons of one-variable data were performed using a two-tailed unpaired 
Student’s t test. Percent starting weight for WT, TLR7-/- and Myd88-/- mice was analyzed 
using a one-way ANOVA with multiple comparisons corrections (P<0.01 is considered 
significant). Clinical scores for WT, TLR7
-/-
 and Myd88
-/-
 mice were analyzed by Mann-
Whitney analysis with Bonferroni’s correction (P<0.01 is considered significant). Bar 
graphs represent mean values ± standard deviation. Significant differences are 
represented by comparison (*) with the following legend: *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001, unless otherwise indicated. 
 
2.4 Results 
 
Myd88 mediates protection from RRV-induced disease.  
Previous studies have shown that the host inflammatory response plays a major 
role in the pathogenesis of alphavirus-induced arthritis and myositis (51, 56-59, 175). To 
further define the host pathways that contribute to alphavirus-induced pathology, we 
evaluated the role of toll-like receptors (TLRs) in a mouse model of RRV-induced 
arthritis/myositis. Because Myd88 is an essential adaptor for signaling through multiple 
TLRs, we evaluated mice deficient in Myd88 for their susceptibility to RRV-induced 
inflammatory disease (194, 197-199). Myd88-deficient (Myd88
-/-
) mice were highly 
susceptible to RRV-induced disease, with Myd88
-/-
 mice developing more severe disease 
signs, as measured by weight loss and clinical disease scores, than wild-type (WT) 
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C57BL/6J animals over the course of infection (Figure 2.1A and 2.1B). Consistent with 
previous studies, RRV-infected WT mice lost weight between days 6 and 10 post-
infection and reached peak disease scores between day 9 and 10 post-infection (Figure 
2.1A and 2.1B). Although Myd88
-/-
 mice showed a similar disease progression, they lost 
more weight and exhibited more severe disease than WT animals over the course of RRV 
infection (Figure 2.1A and 2.1B). Furthermore, while RRV-induced disease is self-
limited in WT animals, with the animals completely recovering from RRV-induced 
disease, 100% of Myd88
-/-
 mice were moribund by day 10 post-infection and had to be 
euthanized. These results suggest that rather than contributing to disease pathogenesis, 
Myd88-dependent signaling plays an essential protective role during RRV infection. 
TLR7-deficient mice exhibit an identical phenotype to Myd88-deficient animals.  
While Myd88 operates as an essential adaptor molecule for most TLRs, it can also 
serve as an adaptor for IL-1 and IL-18 receptor signaling (200, 201). Therefore, it was 
unclear whether Myd88’s protective effect during RRV infection reflected a role for a 
specific TLR or possibly signaling through the IL-1/IL-18 receptors. To address this 
question, we sought to evaluate the role of specific TLRs in the pathogenesis of RRV-
induced disease. These studies initially focused on TLR7, a Myd88-dependent TLR that 
is known to play a role in the antiviral response against multiple viruses, including single-
stranded RNA viruses (90, 194, 202-206). When TLR7
-/-
 mice were infected with RRV, 
they exhibited an identical phenotype to Myd88-deficient animals, with TLR7
-/-
 mice 
losing more weight and developing more severe disease signs than WT mice (Figure 2.1C 
and 2.1D). RRV-infected WT and TLR7
-/-
 mice lost weight between 7 and 10 days post-
infection, with TLR7-/- mice losing weight at a faster rate than WT animals (Figure 
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2.1C). WT and TLR7
-/-
 mice reached peak clinical disease scores between days 9 and 10 
post-RRV infection (Figure 2.1D). However, mice deficient in TLR7 developed disease 
more rapidly than WT animals following RRV infection, and peak disease was more 
severe, with peak disease scores in TLR7
-/-
 mice (5.7 ± 0.4) significantly higher than 
disease scores in WT animals (4.3 ± 0.2) (Figure 2.1D). Similar to Myd88
-/-
 mice, TLR7
-/-
 
mice became moribund by day 10 post-infection and had to be euthanized. Therefore, 
although we cannot rule out a role for other Myd88-dependent TLRs, such as TLR2 or 
IL-1/IL-18 receptor signaling in the pathogenesis of RRV infection, these results indicate 
that TLR7-dependent signaling through Myd88 plays a major protective role during RRV 
infection. 
Tissue damage is enhanced in Myd88- and TLR7-deficient mice following RRV infection.  
 Because skeletal muscle is a targeted tissue for viral replication, inflammation and 
tissue destruction following RRV infection (53, 58, 59), we evaluated the role of TLR7 
and Myd88 in protecting from RRV-induced tissue damage and inflammation. WT, 
TLR7
-/-
 and Myd88
-/-
 mice were sacrificed at 10 days post-infection, which represents the 
time of peak disease in the animals (58, 59, 193), and quadriceps tissues were excised and 
prepared for histological analysis. As shown in Figure 2.2, TLR7
-/-
 and Myd88
-/-
 mice 
showed enhanced tissue damage in skeletal muscle tissue when compared with WT mice 
following RRV infection. While mock-infected animals of all strains showed similar 
levels of resident inflammatory cells and intact muscle fibers in skeletal muscle tissue, 
muscle tissue from TLR7
-/-
 and Myd88
-/-
 mice showed less intact muscle fibers and more 
overall tissue destruction following RRV infection relative to WT mice, despite similar 
levels of inflammation (Figure 2.2A). 
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To quantify the extent of inflammation and damage present in the muscle tissues 
at 10 days post-infection, histological slides were blinded and scored using a blind 
scoring method that assigns scores based on the presence of inflammatory cell infiltrates 
and overall damage in the muscle tissue (Figure 2.2B and 2.2C). The results of the blind 
scoring analyses showed that while WT and TLR7
-/-
 mice showed similar levels of 
inflammatory cell infiltration in skeletal muscle tissue following RRV infection, there 
was significantly more damage in the quadriceps tissue of TLR7
-/-
 mice relative to WT 
mice (Figure 2.2B), and this was also observed following histological scoring of WT and 
Myd88
-/-
 skeletal muscle tissues (Figure 2.2C). However, no differences were observed 
following histological analyses of non-target tissues such as the brain and spinal cord of 
WT, TLR7
-/-
 and Myd88
-/-
 mice at day 10 post-infection (data not shown), suggesting that 
the enhanced tissue damage observed in TLR7- and Myd88-deficient mice is specific to 
RRV-targeted skeletal muscle. These data suggest that TLR7 and Myd88 play a critical 
role in protection from severe skeletal muscle damage following RRV infection. 
TLR7 deficiency does not affect macrophage recruitment but does affect T cell 
recruitment into RRV-infected muscle tissue.  
Previous studies have shown that inflammatory macrophages play a major role in 
promoting RRV-induced disease (51, 57, 175). Although the histological scoring 
analyses revealed similar degrees of inflammation in the skeletal muscle tissue of WT 
and TLR7
-/-
 mice following RRV infection, we sought to more rigorously quantify the 
overall number and composition of inflammatory cells within the skeletal muscle of 
RRV-infected TLR7
-/-
 and WT mice. At 5 and 7 days post-infection, WT and TLR7
-/-
 
mice showed similar numbers of inflammatory leukocyte cell populations, including 
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inflammatory macrophages, in RRV-infected quadriceps tissues as determined by flow 
cytometry (Figure 2.3A and 2.3C). Moreover, total numbers of LCA-positive cells 
isolated from RRV-infected muscle tissues were not different between WT and TLR7
-/-
 
mice at both 5 and 7 days post-infection (data not shown). Analyses of infiltrating 
lymphocytes in the quadriceps muscle tissues revealed a slight decrease in the total 
numbers of lymphocyte cell populations, including B cells and CD4+ T cells, in TLR7
-/-
 
mice when compared to WT mice at 5 and 7 days post-RRV infection (Figure 2.3B and 
2.3D). Additionally, CD3-positive and CD4-positive T cell populations were significantly 
decreased in TLR7
-/-
 mice relative to WT mice at 7 days post-infection (Figure 2.3D). 
Therefore, although TLR7 deficiency did not have a general effect on inflammatory cell 
recruitment, it appears that TLR7 is required for the full recruitment of T cells into the 
inflamed muscle tissue during RRV infection. 
Type I IFN production in sera of TLR7- and Myd88-deficient mice is similar to WT mice 
at early times post-RRV infection.  
TLR7 is known to play an important role in the antiviral response against a wide 
range of viral pathogens, in large part through its ability to regulate type I IFN responses 
(89, 90, 207-211). Because type I IFN receptor signaling is essential for the control of a 
number of alphaviruses (137-139, 212, 213), including RRV (R. Shabman and M.T. 
Heise, unpublished), we evaluated whether TLR7 was required for the early regulation of 
type I IFN responses in vivo. As shown in Figure 2.4, there were no differences in type I 
IFN production between WT and TLR7-deficient animals at 12, 24 and 48 hours post-
infection as measured by Type I IFN bioassay (Figure 2.4A). Moreover, type I IFN 
production was similar between WT and Myd88
-/-
 mice at 24 and 48 hours post-infection 
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(Figure 2.4B), suggesting that the early type I IFN response does not contribute to the 
enhanced disease phenotype observed in TLR7- and Myd88-deficient mice following 
RRV infection. 
Viral titers are elevated in mice lacking TLR7 or Myd88 at late times post-infection. 
 To determine whether viral burden was altered in mice deficient in TLR7 or 
Myd88, we quantified the amount of virus present in the quadriceps and serum of WT, 
TLR7
-/-
 and Myd88
-/-
 mice at various times post-RRV infection. No significant 
differences in viral titer were detected in the quadriceps muscles or serum of WT, TLR7
-/-
 
and Myd88
-/-
 mice at early times post-infection (Figure 2.5). WT and TLR7
-/-
 mice did 
not show significant differences in viral titer in the quadriceps muscles by plaque assay at 
days 0.5, 1, 2 and 3 post-infection (Figure 2.5A). However, viral titers in the serum of 
TLR7
-/-
 mice were significantly enhanced over WT mice at day 3 post-infection (Figure 
5B), and analysis of viral burden in infected quadriceps tissues at later times post-
infection revealed that TLR7
-/-
 mice had significantly higher viral titers than WT mice at 
days 5 and 7 post-infection (Figure 2.5A). Similar results were found in Myd88-deficient 
mice (Fig. 2.5C and 2.5D).  Although viral titers in the quadriceps were similar at day 10 
post-infection in WT, TLR7
-/-
 and Myd88
-/-
 mice (Figure 2.5A and 2.5C), these titers 
were close to or below the limit of viral detection by plaque assay and any differences 
between the strains would thus be difficult to ascertain at this timepoint. Therefore, these 
findings suggest that RRV is able to infect and spread within target tissues of TLR7
-/-
 and 
Myd88
-/-
 mice with kinetics similar to WT animals early during infection, but mice 
lacking TLR7 or Myd88 cannot effectively control viral replication within the muscle 
tissue at later times post-infection. Although RRV-induced disease is characterized by 
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high levels of viral replication within joint and muscle tissues, with subsequent 
overactive inflammatory responses in these tissues contributing to disease pathogenesis 
(51, 53, 58, 59), the inability of TLR7- or Myd88-deficient mice to control viral 
replication at late times post-infection raised the possibility that the enhanced 
disease/mortality in these mice might be due to enhanced viral replication in other tissues, 
such as the central nervous system (CNS). However, we observed no differences in viral 
load within the brain and spinal cord of WT and TLR7
-/-
 mice at 1 and 2 days post-
infection, and viral titers in these tissues were below the limit of detection for both mouse 
strains by day 7 post-infection (data not shown). We also observed no differences in viral 
titer between WT and TLR7
-/-
 mice in the kidney, liver, spleen and draining lymph node 
at 1 and 2 days post-infection (data not shown), suggesting that excess viral replication 
within the CNS or other non-target tissues of RRV infection does not explain the 
enhanced disease observed in TLR7-deficient mice. 
TLR7
-/- 
mice show reduced neutralizing antibody production and decreased antibody 
affinity following RRV infection.  
Because TLR7
-/-
 mice showed enhanced viral titers when compared to WT mice 
at late times post-infection, we hypothesized that deficiency in TLR7 signaling may 
result in an ineffective antibody response that leads to an inability to control viral 
replication during RRV infection. To determine whether deficiency in TLR7 affected 
antibody production following RRV infection, RRV-specific antibody levels were 
quantified in the sera of WT and TLR7
-/-
 mice by ELISA at 7 and 10 days post-infection 
(Figure 2.6A and 2.6B). TLR7
-/-
 mice showed increased RRV-specific total IgG 
production at 7 and 10 days post-infection when compared with WT animals (Figure 
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2.6A and 2.6B), with TLR7
-/-
 mice having significantly increased total RRV-specific IgG 
at day 7 post-infection (Figure 2.6A). Additionally, analysis of RRV-specific IgG 
subtypes revealed that TLR7
-/-
 mice showed significantly increased IgG1 and IgG2c 
antibody production at 7 days post-infection, as well as increased IgG2c antibody levels 
at day 10 post-infection, relative to WT mice (Figure 2.6A and 2.6B). These results 
suggest that RRV-specific antibody production is elevated in TLR7
-/-
 mice following 
RRV infection. Furthermore, because IgG1 is indicative of T-helper 2 (Th2) immune 
responses and IgG2c is indicative of T-helper 1 (Th1) immunity, analysis of RRV-
specific IgG subtypes reveals that TLR7
-/-
 mice have a skewed Th1/Th2 antibody 
response following RRV infection relative to WT mice (Figure 2.6A and 2.6B) (214-
216). 
To determine whether the quality of RRV-specific antibody was altered in TLR7-
deficient mice, we first tested the neutralization capacity of WT and TLR7
-/-
 antisera 
from 7 and 10 days post-RRV infection by PRNT assay (Figure 2.5C). Antisera from 
TLR7
-/-
 mice had significantly less neutralization activity when compare to WT antisera 
at both 7 and 10 days post-infection, suggesting that the quality of RRV-specific antibody 
produced by TLR7-deficient mice is defective and less neutralizing relative to WT 
antibody responses following RRV infection (Figure 2.6C). To further assess the quality 
of RRV-specific antibody in TLR7
-/-
 mice, we determined whether TLR7-deficiency 
altered the affinity of RRV-specific antibody using an Affinity ELISA (Figure 2.7). As 
shown in Figure 2.7, RRV-specific IgG from infected TLR7
-/-
 mice displayed less affinity 
for RRV than WT IgG, suggesting that TLR7-deficiency affects the affinity maturation of 
virus-specific antibody during RRV infection.  
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Lastly, we directly tested whether sera from TLR7
-/- 
mice showed a reduced 
capacity to protect from RRV-induced disease in adoptive transfer studies. We passively 
transferred heat-inactivated sera obtained from WT or TLR7
-/- 
mice at day 10 post-
infection to naïve WT mice prior to RRV infection. As shown in Figure 2.7, the transfer 
of TLR7-deficient antisera failed to protect WT mice from RRV infection (Figure 2.7B 
and C). WT mice that received sera from RRV-infected TLR7
-/-
 mice showed 
significantly reduced weight gain and enhanced disease signs between days 5 and 10 
post-infection compared to mice that received WT antisera, which were protected from 
RRV-induced disease (Figure 2.7B and C). Taken together, these results indicate that 
TLR7 is critically important in the establishment of an effective antibody response 
following RRV infection. 
Myd88- and TLR7-deficiency alters germinal center development following RRV 
infection.  
Germinal center (GC) B cells have been shown to be critical for antibody affinity 
maturation and for the development of class-switched neutralizing antibodies (217). 
Because RRV-specific antibody responses were defective in TLR7-deficient mice, we 
investigated whether GC development was altered in TLR7
-/-
 mice during RRV infection. 
As shown in Figure 2.8, histological analysis of spleens from WT and TLR7
-/-
 mice at 
day 10 post-infection revealed that TLR7
-/-
 mice show reduced GC formation following 
RRV infection. While RRV-infected WT mice exhibited abundant GC structures at 10 
days post-infection, GC formation was visibly reduced in TLR7
-/-
 mouse spleens (Figure 
2.8A). Blind scoring analysis of GC formation also revealed a reduced percentage of GCs 
per follicle in TLR7-deficient mice (Figure 2.8B). To determine whether Myd88-
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dependent TLR7 signaling is important in GC B cell development, we quantified the total 
numbers of GC B cells present in the spleens of WT and Myd88
-/-
 mice at day 9 post-
RRV infection by flow cytometry. As shown in Figure 2.8C, Myd88-deficient mice 
showed significantly reduced GL7+ GC B cells compared to WT mice. These results 
demonstrate that Myd88-dependent TLR7 signaling is critical for germinal center 
development following RRV infection. Furthermore, these findings implicate the 
importance of TLR7 in generating an effective adaptive immune response during RRV 
infection. 
 
2.5 Discussion 
 
The host inflammatory response is known to play a major role in the pathogenesis 
of alphavirus-induced arthritis and myositis, yet the role of specific host sensing 
pathways in regulating these processes has not been investigated in detail. The studies 
presented here demonstrate that TLR7 and its essential adaptor molecule, Myd88, 
mediate protection against severe RRV-induced disease and mortality. Furthermore, both 
TLR7- and Myd88-deficient mice exhibited a defect in viral clearance, and TLR7
-/-
 mice 
failed to mount effective antibody responses against RRV, showing both reduced 
antibody neutralizing activity and reduced RRV-specific antibody affinity. Moreover, 
TLR7
-/-
 mice show reduced germinal center formation, and Myd88-deficient mice show 
reduced germinal center (GL7+) B cells compared to WT animals following RRV 
infection. These results suggest that TLR7-dependent interactions with the adaptive 
immune response play a crucial role in regulating the development of protective immune 
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responses against RRV. Although we cannot rule out a role for other Myd88-dependent 
TLRs, such as TLR2 or IL-1/IL-18 receptor signaling in RRV-induced disease, these 
findings provide new insights into the role that TLR7 plays in alphavirus pathogenesis by 
highlighting the importance of this pathway in regulating antiviral adaptive immunity, 
and by identifying TLR7 as a possible target for enhancing vaccine-induced immune 
responses against alphaviruses. 
To our knowledge, TLR7’s role in alphavirus pathogenesis has not previously 
been investigated. Because type I IFN receptor signaling is important for the control of a 
number of alphaviruses (137-139, 212, 213), we initially focused our analysis on 
evaluating whether TLR7 was required for the early control of RRV infection or 
regulation of the type I IFN response in vivo. Somewhat surprisingly, we found no 
evidence for altered viral loads either in the serum or skeletal muscle at very early to 
intermediate times in the infection process (Figure 2.5), nor did we find evidence for 
enhanced viral replication in other sites, such as the CNS and other non-target tissues, 
that might contribute to exacerbated RRV-induced disease and mortality (data not 
shown). Furthermore, we found no evidence that systemic type I IFN responses were 
decreased in TLR7-and Myd88-deficient animals at early times post-infection as 
measured by Type I IFN bioassay (Figure 2.4), suggesting that other innate sensing 
pathways, such as RIG-I and PKR that are known to be involved in the type I IFN 
response to alphaviruses (166, 218-220), rather than TLR7, may contribute to the early 
antiviral response against RRV. 
In contrast to our findings that TLR7 was not required for the early control of 
RRV replication, we did see significant defects in the ability of both TLR7- and Myd88-
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deficient animals to control RRV replication at late times post-infection. Moreover, 
although TLR7
-/-
 mice were able to mount RRV-specific antibody responses, the virus-
specific antibody produced demonstrated little neutralizing activity and showed less 
affinity for RRV than WT antibody. Moreover, the passive transfer of TLR7-deficient 
antisera failed to protect naïve WT mice from de novo RRV infection, suggesting that 
TLR7 plays a major role in driving the development of protective antibody in response to 
RRV. Because Myd88-dependent TLR7 signaling in B cells has been shown to be 
important in the development of neutralizing antibodies during retrovirus infection (93), 
it is possible that TLR7 signaling is necessary for an effective antibody response to 
multiple viral pathogens. In addition to the impact on neutralizing antibody responses, we 
also found that TLR7-deficiency resulted in a reduction in the number of CD4+ T cells 
recruited into the inflamed muscle tissue (Figure 2.3). This observed decrease in T cell 
recruitment was not due to a general defect in inflammatory cell infiltration in the TLR7
-/-
 
mice because macrophage recruitment was unaffected. Moreover, both TLR7- and 
Myd88-deficient mice showed defects in germinal center formation following RRV 
infection. Because germinal center B cells have been shown to be regulated by CD4+ 
follicular T cells, it is possible that the defect in CD4+ T cell recruitment that we observe 
in TLR7-deficient mice is modulating germinal center formation and B cell function in 
these mice during RRV infection (221). Taken together, these findings provide further 
evidence that Myd88-dependent TLR7 signaling plays a role in regulating multiple 
aspects of the host adaptive immune response Although it remains to be determined 
exactly how TLR7 and Myd88 are modulating RRV-induced adaptive immune responses, 
Myd88 has been shown to be required for efficient cross-presentation of viral antigens by 
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dendritic cells, wherein Myd88-deficiency leads to decreased priming and activation of 
CD8-positive T cells during infection (222). Likewise, stimulation of TLR7 signaling 
during vaccination can improve neutralizing antibody production, and it is possible that 
TLR7 deficiency may also affect neutralizing activity and affinity maturation of 
antibodies during alphavirus infection (96). Importantly, given TLR7’s importance in 
regulating the development of protective anti-RRV responses, these studies suggest that 
enhancing TLR7-mediated responses may be beneficial during vaccination against RRV 
or other alphaviruses. 
TLR7 is expressed on a wide variety of cell types, including macrophages and 
dendritic cell subsets.  Although type I IFN responses in many cell types, including 
myeloid dendritic cells, are independent of Myd88 and therefore TLR7 (223), TLR7 is 
the major driver of type I IFN production by plasmacytoid dendritic cell (pDCs) in 
response to viral infection or RNA ligands (224). Because pDCs are known to express 
high levels of TLR7 and have been shown to recognize ssRNA viruses through TLR7 and 
Myd88, one potential mechanism for the enhanced RRV-induced disease seen in TLR7-
deficient mice is through dysfunctional pDC activity (202, 222, 224, 225). We found no 
defect in the ability of pDCs isolated from TLR7-deficient mice to produce type I IFN in 
response to RRV infection in vitro (data not shown), although it is possible that pDCs 
lacking TLR7 may have other functional defects during RRV infection that we have not 
yet uncovered with our studies. Moreover, a recent study demonstrated the importance of 
Myd88-dependent TLR7 signaling in B cells for the development of effective 
neutralizing antibody production during Friend virus infection (93), and it is possible that 
Myd88 and TLR7 deficiency in B cells may affect neutralizing antibody production 
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during alphavirus infection as well. Studies are ongoing in our lab to assess whether 
TLR7 expression is required for the functional activity of pDCs, B cells and other 
immune cell types to RRV infection. 
These studies clearly demonstrate that TLR7 is required for protection from lethal 
RRV-induced disease and that TLR7 modulated the development of RRV-specific 
adaptive immune responses. However, it is not clear whether the failure to clear RRV 
infection in TLR7-deficient mice can be directly linked to the enhanced disease and 
virus-induced mortality. We have previously shown that RAG-1-deficient (RAG-1
-/-
) 
mice, which lack functional T and B cells, are susceptible to RRV-induced disease (53). 
However, unlike TLR7-deficient animals, RAG-1
-/-
 mice do not die from RRV-induced 
disease (53). This suggests that the lack of a protective adaptive immune response does 
not pre-dispose mice to RRV-induced mortality. This raises two major possibilities, 
where the first is that TLR7 is regulating some aspect of early virus control, such as type 
I IFN responses, that we were unable to detect in our studies. While we cannot rule this 
possibility out, the fact that we did not observe any major changes in viral load at early 
times post-infection argues against this possibility.  It is also possible that some aspect of 
the non-protective adaptive immune response in TLR7
-/-
 animals acts to exacerbate RRV-
induced disease. A similar outcome has been found with respiratory syncytial virus 
(RSV) vaccination, where the lack of Myd88 signaling in response to RSV vaccination 
results in the lack of a protective anti-RSV response within the lungs and leads to the 
development of vaccine-induced immune pathology (226). This may be particularly 
important for RRV because accumulation of immune complexes comprised of antibody-
bound viral particles in TLR7-deficient animals could lead to enhanced complement 
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activation via the classical pathway (227, 228). RRV-mediated inflammatory disease has 
previously been shown to be mediated by complement activation in a mouse model of 
infection, and other arthritic diseases are associated with complement activation as well 
(58, 59, 229, 230). Alternatively, the high titers of non-neutralizing, RRV-specific 
antibodies present in TLR7-deficient mice could enhance RRV infection through an 
antibody-dependent enhancement (ADE) mechanism, resulting in increased Fc-mediated 
uptake of antibody-bound viral particles by phagocytic cells (231). ADE has previously 
been reported to enhance RRV infection of macrophages in vitro, and this mechanism 
could explain the increased viral titers observed in TLR7- and Myd88-deficient animals 
at late times post-RRV infection, correlating with the onset of adaptive immune 
responses (56). Studies are currently underway to determine whether either of these 
possible mechanisms is contributing to the enhanced disease and mortality observed in 
RRV-infected TLR7
-/-
 mice. 
In conclusion, the results of this study identify an essential protective role for the 
Myd88-dependent TLR7 signaling pathway during RRV infection and further define the 
impact of host factors in the pathogenesis of alphavirus-induced arthritis/myositis. Given 
the impact of TLR7 signaling on viral control and on the generation of protective 
adaptive immunity following RRV infection, it may be beneficial to design vaccination 
and treatment strategies for alphavirus infections that enhance Myd88-dependent TLR7 
signaling, such as through the delivery of TLR7 agonists or through stimulation of 
downstream signaling molecules, to ensure optimal protection from alphavirus-induced 
disease. Further studies will be necessary to elucidate the mechanism of TLR7-mediated 
protection from severe RRV-induced disease. 
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Figure 2.1 
 
 
Figure 2.1: TLR7 and Myd88 contribute to protection from RRV-induced disease 
in vivo.  
Twenty-four day old C57BL/6J  wild-type (WT), TLR7
-/-
 and Myd88
-/-
 mice were 
subcutaneously infected in the left rear footpad with either PBS diluent (Mock) or 10
3
 
PFU of RRV and monitored for (A) & (B) weight loss and (C) & (D) clinical disease. N 
= 5-15 mice/strain/timepoint. *P<0.01, **P≤0.001 and *** P≤0.0001. 
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Figure 2.2 
 
Figure 2.2: TLR7- and Myd88-deficient
 
mice show enhanced tissue damage 
following RRV infection.  
Twenty-four day old WT, TLR7
-/- 
and Myd88
-/-
 mice were subcutaneously infected in the 
left rear footpad with either PBS diluent or 10
3
 PFU of RRV. Mice were sacrificed and 
perfused with 4% paraformaldehyde at 10 days post-infection. Quadriceps muscles were 
excised and paraffin-embedded, and 5 µm tissue sections were stained with H&E. (A) 
Histological analysis of mock-infected and RRV-infected quadriceps muscles from WT, 
TLR7
-/- 
and Myd88
-/-
 mice at day 10 post-infection. Representative images are shown. (B) 
Blind scoring of overall inflammatory cell infiltration and damage observed in RRV-
infected WT and TLR7
-/- 
muscle tissue. N = 8 (WT and TLR7
-/-
). (C) Blind scoring of 
overall inflammatory cell infiltration and damage observed in RRV-infected WT and 
Myd88
-/- 
muscle tissue. N = 5 (WT) or 3 (Myd88
-/-). **P≤0.01, ***P≤0.001. 
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Figure 2.3 
 
Figure 2.3: Inflammatory cell recruitment is similar in WT and TLR7
-/- 
mice 
following RRV infection.  
Twenty-four day old WT and TLR7
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. At 5 and 7 days post-infection, mice were sacrificed and 
perfused with 1X PBS. Quadriceps muscles were excised, digested and prepared for flow 
cytometric analysis as described in Materials and Methods. (A) & (C) Total numbers of 
infiltrating inflammatory leukocyte cell populations isolated from RRV-infected WT and 
TLR7
-/- 
quadriceps muscle tissue. (B) & (D) Total numbers of infiltrating lymphocyte cell 
populations isolated from RRV-infected quadriceps muscle tissue. N = 4-7 
mice/strain/timepoint. *P≤0.01. 
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Figure 2.4 
 
Figure 2.4: Type I IFN production in sera of TLR7
-/-
 and Myd88
-/-
 mice is similar 
to WT mice early during infection.  
Twenty-four day old WT, TLR7
-/-
 and Myd88
-/-
 mice were subcutaneously infected in the 
left rear footpad with 10
3
 PFU of RRV. At the indicated timepoints, mice were sacrificed 
by exsanguination and serum was collected. Serum was diluted 1:5 in media and 
analyzed for the presence of Type I IFN (IFN-α/β) by IFN Bioassay as described in 
Materials and Methods. (A) Type I IFN production in sera of WT and TLR7
-/-
 mice. (B) 
Type I IFN production in sera of WT and Myd88
-/-
 mice. N = 3-5 mice/strain/timepoint. 
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Figure 2.5 
 
Figure 2.5: Mice lacking TLR7 or Myd88 show an inability to control viral titer 
at late times post-infection.  
Twenty-four day old WT, TLR7
-/- 
and Myd88
-/-
 mice were subcutaneously infected in the 
left rear footpad with 10
3
 PFU of RRV. At the indicated timepoints, mice were sacrificed 
by exsanguination and quadriceps tissues were dissected. Infectious virus present in (A) 
& (C) homogenized ipsilateral quadriceps tissue and (B) & (D) serum was quantified by 
plaque assay on Vero cells. N = 4-8 mice/strain/timepoint. *P≤0.05, **P≤0.01, 
***P≤0.001. 
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Figure 2.6 
 
Figure 2.6: TLR7
-/- 
mice show reduced neutralizing antibody production 
following RRV infection.  
Twenty-four day old WT and TLR7
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. (A) At 7 and 10 days post-infection, mice were sacrificed 
by exsanguination and serum antibody levels were measured by ELISA as described in 
Materials and Methods. Levels of total RRV-specific IgG, IgG1 and IgG2c antibodies in 
RRV-infected WT and TLR7
-/- 
mice at day 7 (A) and day 10 (B) are shown. (C) At 7 and 
10 days post-infection, mice were sacrificed by exsanguination and sera from RRV-
infected WT and TLR7
-/- 
mice was tested for RRV neutralization activity using PRNT 
assay as described in Materials and Methods. Neutralizing antibody titers are expressed 
as the inverse of the dilution wherein 50% of the virus present was neutralized (PRNT50) 
for a given sample. N = 6 mice/strain/timepoint. *P≤0.05, **P≤0.01, and ***P≤0.001. 
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Figure 2.7 
 
Figure 2.7: TLR7
-/- 
mice shows decreased antibody affinity and fails to protect 
from RRV-induced disease.  
Twenty-four day old WT and TLR7
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. At 10 days post-infection, mice were sacrificed by 
exsanguination and serum antibody levels were measured by ELISA as described in 
Materials and Methods. (A) To measure antibody affinity, inactivated RRV was plated on 
ELISA plates and sera were added at a 1:40 dilution across the plate. Levels of total IgG 
were measured in the presence of increasing concentrations of NaSCN as described in the 
Materials and Methods. Representative data is shown, where n = 4 (WT) or 6 (TLR7
-/-
) 
mice. (B and C) Twenty-four day old WT mice were intraperitoneally inoculated with 50 
µl of heat-inactivated sera from RRV-infected WT or TLR7
-/-
 mice harvested at day 10 
post-infection. At one hour post-serum transfer, mice were subcutaneously infected in the 
left rear footpad with 10
3
 PFU of RRV and monitored for (B) weight loss and (C) clinical 
disease. N = 4 mice/group/timepoint. *P≤ 0.001, **P≤0.0001. 
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Figure 2.8 
 
Figure 2.8: TLR7
-/- 
mice show reduced germinal center formation following RRV 
infection.  
Twenty-four day old WT and TLR7
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. Mice were sacrificed and perfused with 4% 
paraformaldehyde at 10 days post-infection. Spleens were excised and paraffin-
embedded, and 5 µm tissue sections were stained with H&E. (A) Histological analysis of 
mock-infected and RRV-infected spleens from WT and TLR7
-/- 
mice at day 10 post-
infection. Representative images are shown. (B) Blind scoring of germinal centers (GC) 
per follicle observed in WT and TLR7
-/- 
spleens. GCs are indicated by arrows. N = 3 
mice/strain. (C) Twenty-four day old WT and Myd88
-/- 
mice were subcutaneously 
infected in the left rear footpad with 10
3
 PFU of RRV At 9 days post-infection, mice 
were sacrificed and perfused with 1X PBS. Spleens were excised and prepared for flow 
cytometric analysis as described in Materials and Methods. Total numbers of GL7+ B 
cells isolated from RRV-infected WT and Myd88
-/- 
mouse spleens are shown. N = 5 
mice/strain. *P≤0.01.
†
Lauren M. Neighbours, Alan C. Whitmore, and Mark T. Heise. 
Departments of Microbiology & Immunology and Genetics, UNC-Chapel Hill. 
CHAPTER THREE: 
MYD88-DEPENDENT TLR7 SIGNALING PROTECTS MICE FROM 
SYSTEMIC COMPLEMENT- AND ANTIBODY-MEDIATED DISEASE 
FOLLOWING ROSS RIVER VIRUS INFECTION 
 
3.1 Overview 
 
Chikungunya virus and Ross River virus (RRV) are mosquito-borne alphaviruses 
responsible for epidemics of severe acute and chronic musculoskeletal disease in humans. 
The host innate immune system plays an integral role in the pathogenesis of arthritic 
alphaviruses, where some pathways, such as the host complement cascade, exacerbate the 
virus-induced disease process, while other innate signaling pathways protect from virus-
induced disease. We have previously shown that Myd88-dependent signaling through 
TLR7 mediates protection from severe RRV-induced morbidity and mortality, and that 
TLR7 deficiency results in the production of low affinity, non-neutralizing RRV-specific 
antibodies. Here we report that these low affinity antibodies exacerbate the virus-induced 
disease process. TLR7- and Myd88-deficient mice exhibited enhanced antibody and 
complement deposition in skeletal muscle, cardiac, and renal tissues compared to WT 
mice, and Myd88-dependent TLR7 signaling was required for protection from 
myocardial injury and complement-associated pro-inflammatory marker expression. 
Passive transfer experiments demonstrated that RRV-specific antisera from Myd88- or 
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TLR7-deficient mice induced increased morbidity and tissue damage in B cell-deficient 
mice during de novo RRV infection. Furthermore, mice deficient in TLR7 and C1q 
(TLRxC1q DKO), which are unable to trigger antibody-dependent complement 
pathways, did not show enhanced disease following RRV infection, suggesting that 
Myd88-dependent TLR7 signaling protects mice from developing systemic complement-
dependent immune complex disease during RRV infection.  
 
3.2 Introduction 
 
Alphaviruses are single-stranded, positive-sense RNA pathogens that are 
transmitted by mosquitos. These arboviruses cause unpredictable and destructive 
epidemics of human disease, and the global distribution of their arthropod vectors 
continues to pose considerable risks to public health (1). Infections with Old World 
alphaviruses such as chikungunya virus (CHIKV) and Ross River virus (RRV) are 
associated with debilitating symptoms of polyarthritis and myositis, which can persist in 
a subset of individuals for months and in rare cases cause fatalities (15). The chronic 
morbidities generated by arthritogenic alphavirus-induced diseases produce a significant 
health care burden, and better insight into the mechanisms of alphavirus pathogenesis are 
necessary for the development of more effective therapeutics to treat and prevent 
infections.  
Evidence suggests that the arthropathy associated with CHIKV and RRV 
infections is immune-mediated, resulting from the activation of host inflammatory 
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pathways (51, 53, 54, 57, 172, 175, 232, 233). Human cases and mouse models of RRV-
induced arthritis/myositis have demonstrated that complement activation correlates with 
an enhancement in disease (58-60). The complement pathway that is implicated in 
mediating RRV pathogenesis is the lectin pathway, which utilizes the soluble mannose-
biding lectin (MBL) protein to bind carbohydrate moieties on the surface of pathogens 
and mediate activation of the downstream complement cascade (60, 234). Mice deficient 
in the central complement component 3 (C3), complement receptor 3 (CR3), or MBL are 
resistant to RRV-induced morbidity and tissue damage, while mice deficient in 
components of the classical pathway (C1q) or the alternative pathway (Factor B) of 
complement activation develop disease similar to wild-type (WT) mice (58-60). 
Moreover, serum MBL concentrations are enhanced in RRV-infected individuals and 
directly correlate with severity of RRV-induced polyarthritis (60). 
Additionally, toll-like receptors (TLRs), which are innate immune receptors that 
recognize pathogen-associated molecular patterns on microbes, also play a role in the 
development of RRV-induced disease (64, 235). Upon stimulation by foreign pathogens 
or other TLR ligands, TLRs mediate signal transduction to promote antiviral responses 
such as type I interferon and pro-inflammatory cytokine signaling (64). We recently 
demonstrated that TLR7, which recognizes ssRNA, and its sole adaptor molecule, 
myeloid differentiation primary response gene 88 (Myd88), mediate protection from 
severe RRV-induced morbidity and mortality (64, 235). Furthermore, despite showing 
high titers of virus-specific antibodies, TLR7
-/-
 mice produced lower affinity and less 
neutralizing RRV-specific antibodies, indicating that Myd88-dependent TLR7 signaling 
is critical for the development of protective adaptive immune responses to RRV infection 
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(235). However, the mechanism(s) of exacerbated RRV-induced disease in TLR7-
deficient mice have not been reported. 
To determine the mechanism of enhanced disease in the absence of Myd88-
dependent TLR7 signaling, we evaluated whether the defective antibody responses in 
TLR7-deficient mice were directly inducing pathology during RRV infection. Because 
mice that lack functional B cells (µMT) show a similar disease progression as WT mice 
during RRV infection, we first assessed whether passive transfer of RRV-specific 
antisera from TLR7- or Myd88-deficient mice was protective or pathologic in infected 
µMT mice. The data reported here demonstrate that RRV-specific antisera from TLR7
-/- 
mice induced increased morbidity and tissue destruction than WT antisera in µMT mice 
during de novo RRV infection. Additionally, TLR7- and Myd88-deficient mice exhibited 
enhanced antibody and complement deposition in RRV-infected skeletal muscle tissue, 
while infected WT mice failed to show antibody deposition. Moreover, mice deficient in 
TLR7 showed substantial focal cardiac pathology, which was also associated with 
antibody deposition and complement-dependent inflammatory activation. Furthermore, 
kidney pathology consistent with complement-dependent immune complex disease was 
evident in RRV-infected Myd88
-/- 
mice, and mice deficient in both TLR7 and C1q 
(TLR7xC1q DKO), which are unable to activate the antibody-dependent classical 
complement pathway, developed disease similar to WT mice following RRV infection. 
Taken together, these data suggest that the Myd88-dependent TLR7 signaling pathway 
protects mice from systemic antibody- and complement-dependent exacerbation of RRV-
induced disease.   
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3.3 Materials and Methods 
 
Virus stocks and cells. Viral infections were performed using the mouse-adapted T48 
strain of Ross River virus (RRV), which were generated
 
from the T48 cDNA infectious 
clone (generously provided by Richard Kuhn,
 
Purdue University) as (55)previously 
described . Titrations of viral stocks were determined by plaque assay on Vero cell 
monolayers, grown in DMEM/F12 (Gibco) with 10% Hyclone FBS, 1% non-essential 
amino acids, 1% Pen/Strep, 2.5% NaHCO3 (Gibco) and 1% L-glutamine, as described 
previously (53).  
Mouse experiments. C57BL/6J wild-type (WT), TLR7-deficient (TLR7
–/–
), Myd88-
deficient (Myd88
–/–
), and µMT mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). C1q-deficient (C1q
-/-
) mice were obtained from Michael Diamond at 
Washington University. Mice deficient in both TLR7 and C1q (TLR7xC1q DKO) were 
generated by our laboratory. All of the mice were maintained on a C57BL/6 background 
and bred in-house. All of the mouse studies were performed in
 
a biosafety level 3 
laboratory in accordance with
 
UNC-CH Institutional Animal Care and Use Committee 
guidelines. Twenty-four day old mice were
 
used for all in vivo RRV infection studies and 
infections were performed as described previously (235). Briefly, mice were anesthetized
 
with isoflurane (Halocarbon Laboratories) prior to subcutaneous footpad inoculation with 
10 µl of 10
3
 PFU of RRV in phosphate-buffered
 
saline (PBS) diluent or mock-infected 
with PBS diluent alone. Mice were monitored
 
daily for weight loss and clinical disease 
signs. Clinical disease
 
was scored on a scale from 0-5 by assessing grip strength, hind-
limb weakness
 
and altered gait as described previously (53, 235).  
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Passive serum transfer. Twenty-four day old WT, TLR7
-/-
 and Myd88
-/-
 mice were 
subcutaneously infected in the left rear footpad with 10
3
 PFU of RRV and subsequently 
harvested at day 10 post-infection by exsanguination. Serum from each strain of infected 
mice was collected, pooled according to strain, and heat-inactivated at 56ºC for 1 hour. 
Twenty-four day old naïve µMT mice were then subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV and received intraperitoneal inoculations at 4, 6, and 8 
days post-RRV infection with 50 µl of the heat-inactivated WT, TLR7
-/-
 or Myd88
-/-
 
antisera. All of the infected mice were monitored daily for weight loss and disease signs 
as described above. 
Histological analysis. At 10 days post-infection, mice were sacrificed and perfused with 
4% paraformaldehyde, pH 7.3, and tissues were excised for histology. Excised tissues 
were paraffin-embedded, and 5-µm sections were prepared and stained with hematoxylin 
and eosin (H & E) (53). 
 
Immunohistochemistry (IHC) staining. Mock- and RRV-infected animals were 
sacrificed at 10 days post-infection and perfused with 4% paraformaldehyde, pH 7.3. 
Excised tissues were paraffin-embedded, and 5-µm unstained sections were prepared. To 
determine the extent of complement or antibody deposition in RRV-infected tissues, the 
sections were deparaffinized in xylene, rehydrated through an ethanol gradient, and then 
probed with a goat anti-mouse complement component 3 (C3) polyclonal antibody 
(1:500, Cappel) or a goat anti-mouse immunoglobulin (IgG) antibody (1:500, Southern 
Biotech) using the Vectastain ABC-AP kit (Vector Labs, CA) and the Vector Blue 
alkaline phosphatase substrate kit (Vector Labs, CA) according to the manufacturers' 
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instructions. Sections were then counterstained with Gill's hematoxylin. C3 or IgG 
deposition is indicated by a dark blue/violet stain within the tissues.  
DNP-KLH Immunizations. 8-10 week old WT and TLR7
-/-
 mice were anesthetized with 
isoflurane and immunized subcutaneously with a formulation of dinitrophenyl (DNP) 
conjugated to keyhole limpet hemocyanin (KLH) (DNP-KLH, Calbiochem) with alum at 
1 µg of DNP/mouse. Immunized mice were boosted at 3 weeks post-prime (wpp) with 1 
µg/mouse DNP-KLH only. Sera was collected from the mice via tail bleeding at 1 wpp, 3 
wpp, 1 week post-boost (wpb), and 3 wpb, heat-inactivated at 56 ºC for 1 hour, and then 
stored at 4°C until used for subsequent analyses. 
Enzyme-linked immunosorbent assay (ELISA). Quantitation of antibody titers was 
performed by ELISA as described previously, with minor modifications (235). Briefly, 
DNP-specific antibody titers in the sera of WT and TLR7
-/-
 DNP-KLH immunized mice 
were determined by ELISA using DNP-coated (1µg/ml) high-binding 96-well plates. The 
serum was first diluted 50 to 100-fold and then further diluted by two-fold serial 
dilutions. ELISA antibody titers are expressed as the estimated dilution factor that gave 
an OD450 = 0.2, which is obtained following nonlinear regression analysis of the serial 
dilution curve. Antigen-bound antibody is detected using an HRP-conjugated goat anti-
mouse secondary antibody (Abcam, Cambridge, MA) and ABTS substrate (Invitrogen). 
Antibody Affinity ELISA. Antibody affinity ELISAs were performed as previously 
described, with minor modifications (235). In brief, DNP-specific antibody titers in the 
sera of WT and TLR7
-/-
 DNP-KLH immunized mice were first determined by ELISA as 
described above. To determine antibody affinity, sera was diluted in antibody diluent 
(PBS containing 0.05% Tween-20 and 10% Sigma Block), plated on DNP-coated 
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(1µg/ml) high-binding 96 well plates at an optimal dilution to obtain maximum antibody-
antigen binding, and then incubated at 4ºC for 2 hours. Following the incubation period, 
the plates were washed and increasing concentrations of sodium thiocyanate (NaSCN) 
were added to the plate to serially dissociate the antibody-antigen complexes. The plates 
were washed and then incubated with an HRP-conjugated secondary IgG antibody, 
washed, and then incubated with the substrate as described in the ELISA protocol above. 
Values were reported as the percent maximum total IgG binding at each NaSCN 
concentration. 
Statistical analyses. Data were analyzed using Prism software (GraphPad Software, 
Inc.). Comparisons of one-variable data were performed using a two-tailed unpaired 
Student’s t test. Percent starting weight was analyzed using a one-way ANOVA with 
multiple comparisons corrections (P<0.01 is considered significant). Clinical scores were 
analyzed by Mann-Whitney analysis with Bonferroni’s correction (P<0.01 is considered 
significant). Bar graphs represent mean values ± standard deviation. Significant 
differences are represented by comparison (*) with the following legend: *P≤0.01, 
**P≤0.001, unless otherwise indicated. 
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3.4 Results 
 
Passive transfer of antisera from TLR7- and Myd88-deficient mice is pathologic in B 
cell-deficient mice during de novo RRV infection.  
Host innate immune pathways are critical mediators of arthritogenic alphavirus-
induced disease (51, 56-59, 175). We have previously shown that the Myd88-dependent 
TLR7 signaling pathway protects mice from severe RRV-induced disease and mortality, 
and TLR7 signaling is required for the development of protective, neutralizing virus-
specific antibody responses (235). We have also shown that µMT mice, which lack 
functional B cells, do not show enhanced disease following RRV infection (53). Because 
Myd88- and TLR7-deficient mice showed enhanced non-neutralizing virus-specific 
antibody responses, we hypothesized that perhaps the low affinity, non-neutralizing 
antibody produced by the knockout mice was resulting in antibody-mediated 
immunopathogy (236). To determine whether the RRV-specific antibody induced in the 
absence of Myd88-dependent TLR7 signaling was pathologic in the context of infection, 
we evaluated the effects of passively transferred RRV-specific antisera from C57BL/6J 
wild-type (WT), Myd88-deficient (Myd88
-/-
) and TLR7-deficient (TLR7
-/-
) mice into 
µMT mice during de novo RRV infection. As shown in Figure 3.1, passive transfer of 
RRV-specific antisera from TLR7- or Myd88-deficient mice to RRV-infected µMT mice 
resulted in increased weight loss and clinical disease scores compared to mice that 
received WT antisera (Figure 3.1A-D). Although the antisera from all of the strains 
induced disease signs in the µMT mice, mice that receive antisera from Myd88
-/-
 mice 
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showed significantly enhanced disease compared to the mice that received WT antisera 
(Figure 3.1D).  
Moreover, histological analysis of the quadriceps tissues from the RRV-infected 
µMT at day 10 post-infected revealed that the mice that received antisera from TLR7
-/-
 
mice showed profoundly more skeletal muscle damage compared to the mice that 
received WT antisera (Figure 3.1E). The µMT mice that received antisera from TLR7-
deficient mice showed significant skeletal muscle destruction and pronounced tissue 
necrosis, which was absent in the mice that received WT antisera (Figure 3.1E). 
Furthermore, because antibody-antigen complexes can deposit in renal tissues and induce 
kidney pathology, we analyzed the kidneys from RRV-infected µMT mice that received 
WT or Myd88-deficient antisera (237). While mice that received WT antisera showed 
normal kidney morphology, with round intact glomeruli and ordered interstitial spaces, 
mice that received antisera from Myd88-deficient mice showed collapsed, deformed 
glomeruli and dysregulated interstitial spaces with evidence of tissue necrosis (Figure 
3.1F). Taken together, these data indicate that the antisera from Myd88- and TLR7-
deficient mice induced increased weight loss and tissue damage in µMT mice during de 
novo RRV infection. Furthermore, because the sera was heat-inactivated prior to 
performing the passive transfer experiments, these findings suggest that the antibody 
present in the RRV-specific antisera from Myd88- and TLR7-deficient mice was 
responsible for the enhanced pathology observed in µMT mice.  
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TLR7- and Myd88-deficient mice show enhanced IgG and C3 deposition in RRV-infected 
muscle tissue.  
It is known that antibody generated during viral infection can bind to infected 
cells and exert several functions to mediate cell death (236). Additionally, we have 
previously demonstrated that Myd88- and TLR7-deficient mice show significantly 
enhanced RRV-induced tissue damage compared to WT mice (235). Because antisera 
from Myd88- and TLR7-deficient mice was pathologic in RRV-infected µMT mice, we 
hypothesized that the pathologic antibody was forming immunoglobulin (IgG) complexes 
and depositing on RRV-infected tissue, leading to exacerbated antibody-induced cellular 
cytotoxicity. To address whether antibody deposition was occurring in the tissues of 
Myd88- and TLR7-deficient mice during RRV infection, we performed 
immunohistochemistry (IHC) staining for IgG on RRV-targeted skeletal muscle tissues 
from WT, Myd88
-/-
, and TLR7
-/-
 mice at day 10 post-RRV infection. The IHC analyses 
demonstrated that Myd88- and TLR7-deficient mice showed substantial IgG deposition 
in quadriceps tissues following RRV infection, while WT-infected skeletal muscle tissue 
failed to show IgG deposition (Figure 3.2).  
Complement activation is known to play an important role in RRV pathogenesis 
(58-60). Additionally, antibody complex formation can result in complement fixation and 
activation, a reaction known as serum sickness, which leads to inflammatory responses 
that typically result in cellular cytotoxicity (238-240). Because antibody deposition can 
induce complement-dependent cytotoxicity (CDC), we sought to determine whether 
complement deposition was enhanced in Myd88- and TLR7-deficient mice during RRV 
infection (236). Therefore, we performed IHC analyses on RRV-infected quadriceps 
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tissues from WT, Myd88
-/-
, and TLR7
-/-
 mice to determine the extent of complement 
deposition as indicated by the presence of the central complement component 3 (C3). As 
shown in Figure 3.2, RRV-infected skeletal muscle tissue from Myd88- and TLR7-
deficient mice showed considerably more C3 deposition than RRV-infected tissues from 
WT mice (Figure 3.2). Taken together, these results indicate that both antibody and 
complement deposition is enhanced in the skeletal muscle tissue of Myd88- and TLR7-
deficient mice following RRV infection. Moreover, the increased antibody and 
complement deposition observed directly correlates with the enhanced skeletal muscle 
damage incurred in Myd88- and TLR7-deficient mice, suggesting that Myd88-dependent 
TLR7 signaling protects mice from antibody-mediated CDC during RRV infection.  
Myd88- and TLR7-deficient mice show severe cardiac muscle damage following RRV 
infection.  
Following RRV infection, mice deficient in Myd88 or TLR7 succumb to virus-
induced disease by 10 days post-infection, while WT mice recover from the infection and 
are indistinguishable from mock-infected animals by 30 days post-infection (53, 235). 
Additionally, Myd88- and TLR7-deficient mice show aberrant adaptive immune 
responses to RRV infection, and dysregulated immune responses to viral infection can 
reportedly result in cardiomyopathy and cardiac arrest (235, 241, 242). Therefore, we 
examined cardiac tissues from RRV-infected WT, Myd88
-/-
, and TLR7
-/-
 mice to 
determine whether RRV infection resulted in myocardial damage in the absence of 
Myd88-dependent TLR7 signaling. Histological analyses of cardiac muscle tissue at 10 
days post-infection from WT, Myd88
-/-
, and TLR7
-/-
 mice revealed that Myd88- and 
TLR7-deficient mice developed severe myocardial pathology during RRV infection, 
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which is absent in WT mice (Figure 3.3). While RRV-infected cardiac tissue from WT 
mice appeared similar to mock-infected tissues, the myocardial tissues from Myd88- and 
TLR7-deficient mice contained multiple focal lesions of necrotic tissue (Figure 3.3). 
Thus, these results demonstrated that Myd88-dependent TLR7 signaling prevents the 
development of myocardial damage during RRV infection.  
Cardiac damage in TLR7-deficient mice is induced by antibody-mediated complement 
activation during RRV infection.  
Non-neutralizing antibody induced by viral infection can promote tissue 
pathology and can lead to cardiac disease in the case of coxsackieviruses (243). Because 
Myd88- and TLR7-deficient mice exhibited cardiac pathology following RRV infection, 
we hypothesized that the high level of low-affinity, non-neutralizing antibody produced 
in the deficient animals could be depositing on RRV-infected cardiac muscle and 
inducing the observed pathology. As shown in Figure 3.4, the myocardial tissues from 
TLR7- and Myd88-deficient mice showed focal IgG deposition at 10 days post-RRV 
infection, while IgG deposition was not detected in WT cardiac tissues (Figure 3.4A). 
Moreover, because we detected both IgG and C3 deposition in the skeletal muscle tissue 
of RRV-infected TLR7- and Myd88-deficient mice, we further probed the cardiac tissues 
of Myd88- and TLR7-deficient mice for C3 deposition. Although C3 deposition was not 
present in WT cardiac tissues, mice deficient in Myd88 or TLR7 showed significant C3 
deposition in myocardial tissues (Figure 3.4A). These findings indicate that deficiency in 
Myd88-dependent TLR7 signaling during RRV infection results in antibody and 
complement deposition in myocardial tissues, and antibody-mediated CDC may result in 
cardiac damage in the RRV-infected Myd88- and TLR7-deficient mice. 
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 Complement and inflammatory cytokine activity in the heart has been linked to 
cardiac dysfunction and damage (244-249). Because C3 deposition was prominently 
detected in the cardiac tissues of Myd88- and TLR7-deficient mice following RRV 
infection, we sought to assess the expression levels of C3 and other inflammatory 
markers in RRV-infected myocardial tissues by quantitative real-time PCR (qRT-PCR). 
The qRT-PCR analyses revealed that TLR7
-/-
 mice showed upregulation of C3 and 
multiple pro-inflammatory markers in cardiac tissues at 2 and 7 days post-RRV infection 
(Figure 3.4B). At 2 days post-infection, IL-6 and Arginase-1 (Arg1) expression was 
significantly upregulated in TLR7-deficient mice compared to WT mice (Figure 4B). 
Additionally, IL-1β, TNF, and the calgranulins, s100A8 and s100A9, were increased in 
the myocardial tissues of TLR7
-/-
 mice relative to WT mice at 2 days post-RRV infection 
(Figure 3.4B). Furthermore, the expression levels of s100A8, s100A9, and Arg1 were 
enhanced in the cardiac tissues of TLR7-deficient mice at 7 days post-infection (Figure 
3.4B). These results suggest that deficiency in Myd88-dependent TLR7 signaling results 
in pro-inflammatory responses that may damage or suppress cardiac function during 
RRV infection.  
Myd88-deficient mice show IgG and C3 deposition in the kidneys following RRV 
infection.  
Immune complex formation associated with serum sickness can generate kidney 
pathology (237). Additionally, C3 expression that is induced by antibody-associated 
complexes in the kidney is associated with renal injury (237, 250). To determine whether 
Myd88
-/-
 mice developed immune complex-associated nephropathology following RRV 
infection, we performed IHC analyses on kidneys obtained from WT and Myd88-
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deficient mice at 10 days post-RRV infection (Figure 3.5). While RRV-infected WT mice 
failed to show IgG or C3 deposition, the glomeruli and interstitial regions of the kidneys 
from Myd88-deficient mice showed both IgG and C3 deposition, indicative of immune 
complex deposition (Figure 3.5). Additionally, histological analyses of the kidneys 
revealed normal renal anatomy in the RRV-infected WT mice. However, several 
glomeruli in the Myd88-deficient mice appeared abnormally shaped and collapsed 
following RRV infection (Figure 3.5). Mock-infected kidneys showed normal renal 
anatomy and looked similar to RRV-infected WT kidneys (data not shown). Therefore, 
these results indicate that Myd88-deficient mice develop immune complex-induced renal 
disease during RRV infection. 
C1q mediates enhanced disease in TLR7-deficient mice during RRV infection.  
Because Myd88- and TLR7-deficient mice showed evidence of systemic 
complement- and antibody-mediated pathology during RRV infection, we hypothesized 
that the antibody-mediated CDC was resulting from the classical complement pathway, 
wherein C1q binds to antibody complexes to trigger downstream complement activation 
(234). Additionally, because C1q-deficient mice develop disease similar to WT mice 
following RRV infection, we hypothesized that in the absence of C1q, TLR7-deficient 
mice would not exhibit enhanced RRV-induced disease (60). Thus, we generated mice 
that were deficient in both TLR7 and C1q (TLR7xC1q DKO) and observed them over a 
10-day timecourse of RRV infection. Following RRV infection, mice deficient in TLR7 
and C1q developed a disease similar to WT mice, showing comparable weight loss and 
clinical scores (data not shown). Additionally, histological analyses of quadriceps 
muscles revealed that TLR7xC1q DKO mice did not show enhanced tissue destruction 
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compared to WT tissues at 10 days post-RRV infection (Figure 3.6). While Myd88
-/-
 
mice showed profound destruction of skeletal muscle tissue, the skeletal muscle tissues of 
TLR7xC1q DKO mice were less damaged than that of Myd88-deficient mice and showed 
a similar degree of damage to the skeletal muscle tissues of WT and C1q
-/-
 mice (Figure 
3.6).   
These data indicate that C1q mediates antibody-mediated CDC in TLR7-deficient mice 
and further that Myd88-dependent TLR7 signaling is required for protection from 
systemic antibody-mediated CDC during RRV infection. 
 
3.5 Discussion 
 
 We have previously shown that Myd88-dependent TLR7 signaling mediates 
protection from severe RRV-induced morbidity and mortality and that TLR7 is required 
for the development of a protective adaptive immune response to RRV infection (235). 
However, the mechanism of RRV-induced disease enhancement that occurs in the 
absence of Myd88-dependent TLR7 signaling had not yet been elucidated. The studies 
described herein demonstrate that Myd88-dependent TLR7 signaling is required for 
protection against systemic antibody- and complement-associated disease during RRV 
infection. The passive transfer of antisera from RRV-infected TLR7- and Myd88-
deficient mice resulted in enhanced morbidity and tissue pathology in B cell-deficient 
mice, and both TLR7- and Myd88-deficient mice exhibited pronounced antibody-
associated complement deposition in RRV-infected skeletal muscle tissues. Furthermore, 
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RRV-infected mice developed severe myocardial damage in the absence of TLR7 or 
Myd88, and both antibody and complement deposition was observed in the diseased 
cardiac tissues of TLR7- and Myd88-deficient animals following RRV infection. 
Additionally, the expression of complement and other pro-inflammatory markers such as 
IL-6, TNF-α, and IL-1β that are associated with myocardial suppression were 
significantly enhanced in the cardiac muscles of TLR7-deficient mice (245-248). 
Nephrological analyses revealed antibody and complement deposition in the kidneys of 
RRV-infected Myd88
-/-
 mice, indicative of immune complex deposition, and Myd88
-/-
 
mice presented evidence of renal pathology following RRV infection. Moreover, mice 
deficient in both TLR7 and C1q (TLR7xC1q DKO) did not show enhanced RRV-induced 
morbidity, suggesting that the exacerbated disease exhibited in infected TLR7-deficient 
mice is directly attributed to complement activation via the classical pathway. Therefore, 
these findings suggest that Myd88-dependent TLR7 signaling protects against immune-
mediated enhancement of RRV-induced disease, and deficiencies in TLR7 signaling may 
lead to systemic antibody-mediated CDC during RRV infection.  
 The role of complement in mediating RRV-induced disease is well established 
(58-60). Previous reports have indicated that RRV infection results in MBL-dependent 
complement activation via the lectin pathway, which is activated by pathogen-associated 
carbohydrate moieties and is an antibody-independent mechanism of complement 
activation (60). Our data suggests that in the absence of Myd88-dependent TLR7 
signaling, RRV infection results in antibody-dependent complement activation via the 
C1q-mediated classical pathway of the complement cascade. Moreover, while 
complement-mediated disease is restricted to the skeletal muscle tissue in RRV-infected 
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WT mice, mice deficient in Myd88 or TLR7 showed systemic manifestations of 
antibody-dependent CDC following RRV infection, with cardiac- and kidney-associated 
pathology. Furthermore, the antibody and complement deposition observed in the kidneys 
of RRV-infected Myd88
-/- 
mice suggests that Myd88 deficiency leads to immune 
complex-induced serum sickness during RRV infection. Although complement fixation 
associated with serum sickness can be mediated by cellular infiltrates such as 
macrophages or neutrophils, we did not observe extensive renal inflammation that could 
explain leukocyte-mediated C3 deposition in the kidneys of RRV-infected Myd88-
deficient mice (240). However, the observed complement deposition in Myd88-deficient 
mice can be explained through local production of C3 by glomerular epithelial or 
mesangial cells in the kidney (237, 240). Because renal glomerular cells express Fc 
receptors, they are capable of binding IgG from immune complexes and mediating 
complement expression. Additionally, the role of local complement production in renal 
disease is well-documented, and immune complex-mediated kidney disease has been 
observed in the absence of cellular inflammation (240). 
 Although Myd88 signaling reportedly induces cardiac damage in animal models 
of myocardial injury, this is the first study that we are aware of to demonstrate the role of 
Myd88 in protecting from myocardial disease during viral infection. Interestingly, there 
is limited evidence from severe disease cases that arthritogenic alphaviruses may play a 
role in the development or exacerbation of myocardial damage (251, 252). In one study, a 
young child was diagnosed with myocarditis and congestive heart failure associated with 
a severe CHIKV infection (252). Additionally, multiple cases of severe CHIKV-induced 
disease and fatalities have been associated with cardiomyopathy and/or heart failure, 
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some of whom had no evidence of pre-existing heart conditions or other co-morbidities 
(251, 253). Therefore, severe cases of arthritogenic alphavirus infections may lead to 
systemic complications that induce or exacerbate cardiac disease, and Myd88-dependent 
TLR7 signaling may protect from cardiac injury associated with alphavirus infection. In 
contrast, Myd88-deficient mice show reduced susceptibility to coxackievirus-induced 
myocarditis, indicating that the role of Myd88-dependent signaling in virus-associated 
cardiac injury may be dependent on the infectious agent (254). 
Because Myd88- and TLR7-deficient mice exhibit increased viral loads in skeletal 
muscle tissues late during RRV infection, we hypothesized that the cardiac muscle 
pathology observed in the absence of Myd88 or TLR7 was attributable to enhanced viral 
loads in myocardial tissues (235). However, plaque assay analyses revealed similar viral 
loads in the cardiac tissues of WT, Myd88
-/-
, and TLR7
-/-
 mice early during RRV 
infection, and virus was undetectable in by 5 days post-infection in all of the strains (data 
not shown). Cases of fatal virus-associated myocardiac disease have been reported in the 
absence of infectious virus, such as with B19 parvovirus, encephalomyocarditis virus 
coxackievirus infections (249, 255). Although we do not detect infectious virus in the 
cardiac tissue late during infection, it is possible that the viral RNA may persist in the 
cardiac tissue at low levels and is sufficient to induce antibody-mediated CDC. This 
phenomenon has been demonstrated with picornavirus infections, whereby persistent 
viral genomic material in cardiac tissue can induce inflammatory responses such as 
myocarditis (249, 256, 257). Further studies will be necessary to determine whether the 
myocardial injury observed in Myd88- and TLR7-deficient mice is dependent on 
persistent viral RNA expression. 
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Myd88-dependent TLR7 signaling has been demonstrated to be required for 
efficient neutralizing antibody production by B cells during multiple viral infections, 
including alphavirus infections (80, 93, 96, 235). Thus, one mechanism to explain 
antibody-mediated CDC in the cardiac tissues of Myd88- and TLR7-deficient mice in the 
absence of viral replication or RNA persistence could be through epitope spreading, 
whereby autoantibodies to host tissues are produced during viral infection and can cross 
react with other host tissues (249, 258). In this model, autoantibodies produced during 
RRV infection in the absence of TLR7 signaling could be directed towards skeletal 
muscle antigens such as myosin, and these muscle-directed antibodies may cross-react 
with cardiac muscle tissue and lead to cardiac tissue damage. Follow-up studies will be 
needed to determine whether autoantibodies are generated in TLR7- and Myd88-deficient 
mice during RRV infection. 
Some reports suggest that TLR stimulation promotes B cell differentiation and 
germinal center responses, which enables activated B cells to undergo somatic 
hypermutation and class switch recombination to produce affinity-matured, antigen-
specific antibodies (80). Additionally, TLR7 deficiency leads to defective germinal center 
formation during retrovirus and alphavirus infections in mice, resulting in the production 
of antibody with reduced affinity and neutralization capacities for viral antigens (93, 
235). However, because the role of TLR7 in B cell antibody functionality has only been 
reported in response to viruses or TLR7 agonists, we sought to determine whether TLR7 
deficiency could affect the quality of antibody produced in response to antigens that are 
not known to directly stimulate TLR7 (93, 96, 235, 259, 260). Thus, we immunized WT 
and TLR7-deficient mice with a hapten-protein conjugate formulation of DNP-KLH on a 
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prime-boost schedule and found that DNP-specific antibody from TLR7
-/-
 mice showed 
significant defects in antigen affinity at 1 week post-prime compared to the antibody 
from WT mice, despite showing similar levels of total DNP-specific IgG throughout the 
experiment (3.7A and B). However, DNP-associated antibody affinity was improved in 
TLR7-deficient mice following a secondary immunization, and the antibody generated 
from immunized WT and TLR7-deficient mice showed similar degrees of affinity for the 
immunogen at 1 week post-boost (3.7C). These findings are supported by a study 
demonstrating that Myd88-deficient mice, which are susceptible to primary influenza 
virus infection, are resistant to secondary infection when primed with a non-lethal dose of 
influenza virus (261). These results provide additional evidence that TLR7 plays a broad 
role in regulating antibody efficiency and suggest that therapeutic approaches to improve 
TLR7 signaling may aid in the development of protective humoral responses to vaccines 
and viral infections.  
In summary, the data reported in this study demonstrate that Myd88-dependent 
TLR7 signaling protects mice from systemic antibody- and complement-mediated disease 
during RRV infection. Given the significant role that TLR7 signaling plays in the 
development of effective antibody responses to viral and non-viral stimuli, therapeutic 
strategies aimed at enhancing antibody efficacy may benefit from TLR7-directed 
stimulation. 
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Figure 3.1 
 
Figure 3.1: Passive transfer of antisera from TLR7- and Myd88-deficient mice is 
pathologic in B cell-deficient mice during de novo RRV infection.  
Twenty-four day old B cell-deficient µMT mice were subcutaneously infected in the left 
rear footpad with 10
3
 PFU of RRV and monitored for (A) & (C) weight loss and (B) & 
(D) clinical disease. At 4, 6, and 8 days post-infection, RRV-infected µMT mice received 
50 µl intraperitoneal inoculations of  RRV antisera from (A) & (B) day 10-infected 
C57BL/6J wild-type (WT) and TLR7
-/- 
mice or (C) & (D) day 10-infected WT and 
Myd88
-/-
 mice. N = 3-4 mice/strain/timepoint. *P ≤ 0.01 and **P≤0.001. (E) Mice were 
sacrificed and perfused with 4% paraformaldehyde at 10 days post-infection. Quadriceps 
(E) and kidney (F) tissues were excised and paraffin-embedded, and unstained 5 µm 
tissue sections were obtained for histological analyses. Arrows indicate glomeruli. 
Representative images are shown.  
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Figure 3.2 
 
Figure 3.2: TLR7
-/- 
mice show enhanced IgG and C3 deposition in RRV-infected 
muscle tissue.  
Twenty-four day old WT, Myd88
-/-
, and TLR7
-/- 
mice were subcutaneously infected in the 
left rear footpad with either PBS diluent or 10
3
 PFU of RRV. Mice were sacrificed and 
perfused with 4% paraformaldehyde at 10 days post-infection. Quadriceps muscles were 
excised and paraffin-embedded, and unstained 5 µm tissue sections were obtained for 
immunohistochemistry (IHC) and coutnerstained with Gill’s hemotoxylin as described in 
Materials and Methods. IHC staining for murine immunoglobulin (IgG) and complement 
component 3 (C3) deposition in RRV-infected quadriceps muscle tissue is indicated by 
dark blue/violet staining at areas of tissue damage. Representative images are shown.  
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Figure 3.3 
 
Figure 3.3: Myd88- and TLR7-deficient mice show severe cardiac muscle tissue 
damage following RRV infection.  
Twenty-four day old WT, TLR7
-/-
 and Myd88
-/- 
mice were subcutaneously infected in the 
left rear footpad with either PBS diluent or 10
3
 PFU of RRV. Mice were sacrificed and 
perfused with 4% paraformaldehyde at 10 days post-infection. Cardiac tissues were 
excised and paraffin-embedded, and unstained 5 µm tissue sections were obtained for 
histological analyses. Representative images are shown.  
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Figure 3.4 
 
Figure 3.4: Myd88
-
 and TLR7-deficient mice show IgG and C3 deposition in 
cardiac muscle tissue following RRV infection.  
Twenty-four day old WT, Myd88
-/- 
and TLR7
-/-
 mice were subcutaneously infected in the 
left rear footpad with either PBS diluent or 10
3
 PFU of RRV. (A) Mice were sacrificed 
and perfused with 4% paraformaldehyde at 10 days post-infection. Cardiac tissue were 
excised and paraffin-embedded, and unstained 5 µm tissue sections were obtained for 
IHC and coutnerstained with Gill’s hemotoxylin as described in  Materials and Methods. 
IHC staining for IgG and C3 deposition in RRV-infected cardiac tissue from WT, 
Myd88
-/- 
and TLR7
-/-
 mice at day 10 post-infection is indicated by dark blue/violet 
staining at areas of tissue damage. Representative images are shown. (B) & (C) At 2 and 
7 days post-infection, mice were sacrificed by exsanguination and cardiac tissues were 
dissected. Total RNA was isolated from cardiac tissues, reverse transcribed, and analyzed 
for cytokine expression by quantitative Real-time PCR as described in Materials and 
Methods. The inflammatory markers analyzed included IL-1β, IL-6., s100A8, s100A9, 
Arginase-1 (Arg1), TNF, and C3. *P≤0.01 and **P≤0.001. 
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Figure 3.5 
 
Figure 3.5: Myd88
-/- 
mice show IgG and C3 deposition in the kidneys following 
RRV infection.  
Twenty-four day old WT and Myd88
-/- 
mice were subcutaneously infected in the left rear 
footpad with either PBS diluent or 10
3
 PFU of RRV. Mice were sacrificed and perfused 
with 4% paraformaldehyde at 10 days post-infection. Kidneys were excised and paraffin-
embedded, and unstained 5 µm tissue sections were obtained for IHC and coutnerstained 
with Gill’s hemotoxylin as described in Materials and Methods. IHC staining for IgG and 
C3 deposition in RRV-infected kidneys from WT and Myd88
-/- 
mice at day 10 post-
infection is indicated by dark blue/violet staining. Representative images are shown. 
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Figure 3.6 
 
Figure 3.6: TLR7xC1q DKO mice do not show enhanced disease following RRV 
infection.  
Twenty-four day old WT, C1q
-/-
, TLR7xC1q DKO, and Myd88
-/-
 mice were 
subcutaneously infected in the left rear footpad with 10
3
 PFU of RRV. At day 10 post-
infected, mice were sacrificed, and quadriceps tissues were excised and prepared for 
histological analyses as described in Materials and Methods. N = 3-4 mice/strain.  
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Figure 3.7 
 
Figure 3.7: TLR7 regulates antibody affinity responses to non-RNA stimuli. 8-10 
week old WT and TLR7
-/-
 mice were immunized subcutaneously with a formulation of 
dinitrophenyl (DNP) conjugated to keyhole limpet hemocyanin (KLH) with alum at 1 µg 
of DNP/mouse. Immunized mice were boosted at 3 weeks post-prime (wpp) with 1 
µg/mouse DNP-KLH only. Sera was collected from the mice via tail bleeding at 1 wpp, 3 
wpp, 1 week post-boost (wpb), and 3 wpb.(A) Sera from immunized WT and TLR7
-/-
 
mice was analyzed at each indicated timepoint for total DNP-specific IgG titers by 
ELISA as described in Materials and Methods. (B) & (C)  Antibody affinity of DNP-
specific IgG was measured by affinity ELISA as described in Materials Methods at (B) 3 
wpp and (C) 1 wpb. N = 6-8 mice/strain/timepoint. *P ≤0.0001.  
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CHAPTER FOUR: 
TLR4 PROMOTES ROSS RIVER VIRUS-INDUCED DISEASE IN MICE 
 
4.1 Overview 
 
Arthritis-associated alphaviruses, such as chikungunya virus and Ross River virus 
(RRV) are mosquito-transmitted pathogens that cause severe arthritis and myositis in 
infected individuals. Host inflammatory pathways play a major role in regulating the 
alphavirus-induced disease process, with some pathways such as the complement cascade 
contributing to disease, while other pathways such as TLR7-dependent signaling 
mediating protection. To further investigate the role of TLRs in alphavirus-induced 
disease, we evaluated TLR4, which has been linked to other inflammatory diseases, for 
its role in RRV-induced arthritis and myositis. Using a mouse model of RRV-induced 
arthritis/myositis, we evaluated TLR4 deficient mice for disease susceptibility and 
demonstrated that TLR4 is essential for the development of RRV-induced disease and 
inflammatory tissue damage. Despite markedly different outcomes in disease, TLR4-
deficient and WT mice showed similar viral loads throughout the course of infection, 
suggesting that the disease mediated by TLR4 is independent of RRV replication. 
Moreover, TLR4-deficient mice showed reduced complement deposition and activation 
in RRV-targeted skeletal muscle tissue compared to WT mice, and macrophages deficient 
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in TLR4 exhibited reduced expression of complement component 3 (C3) following co-
culture with RRV-infected myotubes. These results demonstrate a unique role for TLR4 
in regulating complement production and subsequent disease development during 
alphavirus-induced arthritis and suggest that specifically targeting TLR4 dependent 
signaling pathways may provide therapeutic benefits in the treatment of alphavirus-
induced arthritis.   
 
4.2 Introduction 
 
Arthropod-bourne alphaviruses are associated with significant outbreaks of 
infectious polyarthritis or encephalitis in humans (4, 5, 45). Furthermore, because of their 
broad vector distribution, many of these viruses, including chikungunya virus (CHIKV) 
and Ross River virus (RRV) are capable of emerging in new regions and causing disease 
outbreaks affecting thousands to millions of individuals (16, 262-265). Although arthritis-
associated alphaviruses are a significant emerging disease threat, there are currently no 
approved vaccines or virus-specific therapies for these viruses.   
Old world arthritogenic alphaviruses such as CHIKV and RRV cause debilitating 
joint and muscle pain, stiffness, and swelling that can result in a chronic disease in some 
individuals (16, 42, 190-192). Inflammatory cells and pro-inflammatory cytokines are a 
prominent feature of RRV and CHIKV infection in humans (15). Mouse models of 
alphavirus-induced arthritis and myositis have demonstrated that the host inflammatory 
response directly mediates alphavirus pathogenesis, with inflammatory macrophages and 
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complement being required for the development of severe disease (51, 56-60, 175). 
Additionally, toll-like receptors (TLRs), which are pattern-recognition receptors that 
recognize conserved pathogen-associated molecular patterns, have been shown to be 
upregulated during alphavirus infection, and TLR7 signaling is required for protection 
from severe arthritogenic alphavirus morbidity and mortality in mice (64, 144, 195, 196, 
235). However, it is currently unclear whether other TLR pathways play a role in the 
pathogenesis of alphavirus infection, and the downstream mechanisms of alphavirus-
induced diseases remain poorly understood. Further characterization of the roles that host 
inflammatory pathways, including TLR responses, play in alphavirus-induced disease 
may lead to the development of targeted therapeutic strategies to treat affected 
individuals (192). 
TLRs are critical mediators of antiviral immunity and have essential roles during 
acute and chronic viral infections (88, 100, 105, 108, 235, 266-276). TLR4, which 
recognizes bacterial lipopolysaccharide and other microbial components, has been 
demonstrated to function in both protective and pathologic capacities during RNA and 
DNA virus infections (100, 103-108). In addition to its varying roles in viral infections, 
TLR4 has been shown to be pathologic in human and mouse models of arthritis, which is 
attributed in part to its role in promoting joint inflammation (119-126). Additionally, two 
complement component 3 (C3)-dependent calgranulins, s100A8 and s100A9, which are 
upregulated during arthritogenic alphavirus infection, have been shown to be upregulated 
in a TLR4-dependent manner in human osteoarthritic chondrocytes and in the synovial 
fluid of osteoarthritic patients (59, 60, 132, 133). Moreover, in vitro studies have 
demonstrated that TLR4 signaling is modulated in a monocyte/macrophage cell line 
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through a direct interaction between the TLR4 signaling complex and mannose binding 
lectin (MBL), which is a critical mediator of complement-dependent alphavirus disease 
(60, 277, 278). 
The aim of this study was to further evaluate the roles of host sensing pathways in 
the development of arthritogenic alphavirus-induced disease. Because TLR4 plays a 
significant role in multiple viral infections and is known to regulate a number of 
inflammatory disease processes, we hypothesized that TLR4 signaling may play a role in 
alphavirus-induced arthritis and myositis. To determine whether TLR4 contributes to 
RRV-induced disease, we evaluated the role of TLR4 in a mouse model of 
arthritis/myositis and found that mice deficient in TLR4 were resistant to RRV-induced 
morbidity. TLR4-deficient mice showed decreased clinical disease and tissue destruction 
compared to RRV-infected wild-type C57BL/6J (WT) mice, despite showing similar 
levels of viral replication in target tissues. Mice deficient in TLR4 also showed reduced 
complement deposition and activation in RRV-infected skeletal muscle tissue, suggesting 
that TLR4 is required for complement-mediated RRV pathogenesis. This was supported 
by results from a novel in vitro co-culture model, whereby we demonstrated that TLR4-
deficient macrophages exhibited decreased complement production following co-culture 
with RRV-infected myotubes. Therefore, these studies indicate that TLR4 plays a major 
role in the pathogenesis of RRV induced disease by regulating the production of 
complement in response to viral infection. 
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4.3 Materials and Methods 
 
Ethics Statement. Mouse studies were performed at University of North Carolina at 
Chapel Hill using protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) in accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health.  
Virus stocks and cells. Ross River virus (RRV) stocks were generated
 
from the mouse-
virulent, full-length T48 cDNA clone (generously provided by Richard Kuhn,
 
Purdue 
University) as previously described (55). Viral titrations were determined by plaque assay 
on Vero cells as described previously (235).
 
Vero cells were grown in DMEM/F12 
(Gibco) supplemented with 10% Hyclone FBS, 1% non-essential amino acids, 1% 
Pen/Strep, 2.5% NaHCO3 (Gibco) and 1% L-glutamine.  
Mouse experiments. C57BL/6J wild-type (WT) and TLR4-deficient (TLR4
–/–
) mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME), and breeding was 
maintained in-house. TLR4
–/– 
mice were maintained on a C57BL/6 background and 
backcrossed onto the C57BL/6 background for an additional five generations (to obtain 
ten-generation backcrossed mice) prior to experimentation. Animal
 
husbandry and 
experiments were conducted according to
 
UNC-CH Institutional Animal Care and Use 
Committee guidelines.
 
All of the in vivo mouse studies were executed in
 
a biosafety level 
3 laboratory and were performed with twenty-four day old mice. Mouse infections with 
RRV were performed as described previously (235). Briefly, mice were anesthetized
 
with 
isoflurane (Halocarbon Laboratories) prior to subcutaneous inoculation in the left
 
rear 
footpad with 10
3
 PFU of RRV in a 10 µl volume of phosphate-buffered
 
saline (PBS) 
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diluent.
 
Mock-infected animals were inoculated with PBS diluent alone. Mice were 
weighed daily and monitored
 
for the development of clinical disease signs. Disease scores
 
were assigned on a scale from 0 to 5 based on gripping ability, hind-limb weakness
 
and 
altered gait as described previously (53, 235).  
Viral titers. Viral titers of RRV-infected tissues were determined by plaque assay as 
described previously (235). Briefly, mice were anesthetized and sacrificed by 
exsanguination. Quadriceps tissues were removed and homogenized, and serum was 
extracted prior to freezing at -80°C until viral titers were determined. Viral tissues were 
thawed on ice and subsequently diluted 10-fold in PBS diluent. 200 µl of the diluted 
samples were pipetted in duplicate into each well of 70% confluent Vero cells in 6-well 
plates. The samples were incubated on the cells for 1 hour at 37°C in a CO2 incubator and 
gently agitated every 15 minutes to ensure an even distribution of the inoculum on the 
cells. After incubation, the cells were overlayed with an agar overlay solution containing 
50% of 2.5% CMC (Sigma), 50% 2X Modified Eagles Media, 3% FBS, 1% Pen/Strep, 
1% L-glutamine and 1% 1M HEPES buffer (Mediatech), and incubated for 48-72 hours 
at 37°C in a CO2 incubator. Cells were then fixed with 4% paraformaldehyde for >2 
hours, counterstained with a 0.25% Crystal Violet solution, and viral plaques were 
counted. 
Histological analysis. At 10 days post-infection, mice were sacrificed and perfused via 
cardiac puncture with 4% paraformaldehyde, pH 7.3. Excised tissues were paraffin-
embedded, and 5-µm sections were prepared. To determine
 
the extent of inflammation 
and tissue pathology, tissues were
 
stained with hematoxylin and eosin (H & E) (53). 
Stained sections
 
were blind-scored for overall inflammatory cell
 
infiltration and tissue 
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damage as described (53, 235). Both scoring systems utilized a 10-point scale wherein 0-
3 represents no to mild inflammation/damage, 4-6 represents moderate 
inflammation/damage, and 7-10 represents severe inflammation/damage.   
Flow cytometry. At 7 and 10 days post-infection, mice were inoculated with RRV as 
described above, sacrificed by exsanguination
 
and perfused extensively with 1X PBS.
 
Quadriceps muscles were excised, minced, and incubated for
 
1.5-2 hours with vigorous 
shaking at 37°C in digestion buffer (RPMI,
 
10% fetal bovine serum, 15 mM HEPES, 2.5 
mg/ml collagenase A
 
[Worthington Biochemical Co.], 17 µg/ml DNase I [Roche]). 
Following digestions, tissue samples were pelleted, resuspended in
 
HFA buffer (Hanks 
balanced salt solution [Gibco], 1% fetal bovine serum, 0.1% sodium azide), passed
 
through a 70 µm cell strainer, and centrifuged
 
for 8 min at 1,000 rpm. Cells were 
resuspended in HFA buffer,
 
and viable cell counts were determined by trypan blue 
exclusion.
 
Isolated cells were incubated with various antibodies, according to the 
associated staining panel, for 30 min to an hour at 4°C in fluorescence-activated
 
cell 
sorter staining buffer (1x Hanks balanced salt solution,
 
1% fetal bovine serum, 2% 
normal rabbit serum). Cells were washed, fixed overnight
 
in 2% paraformaldehyde and 
analyzed on a Cyan cytometer (DAKO-Cytomation) using Summit software. Isolated 
splenocytes from mock-infected animals were prepared similarly and used for single-
color staining controls. The lymphocyte staining panel included the following
 
antibodies: 
anti-NK1.1-phycoerythrin (PE) (eBioscience), anti-CD3-fluorescein
 
isothiocyanate 
(FITC) (eBioscience), anti-B220-PE Texas Red (PETR) (Invitrogen), anti-LCA-PECy5 
(eBioscience), anti-F4/80-PECy7 (eBioscience), anti-CD4-pacific blue (PB) (Caltag 
Laboratories), anti-CD8-pacific orange (PO) (Invitrogen) and anti-CD49b-
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allophycocyanin (APC) (eBioscience). The monocyte staining panel included the 
following antibodies: anti-Ly6G-FITC (BD Pharmingen), anti-SigLecF-PE (BD 
Pharmingen), anti-CD11c-PETR (Invitrogen), anti-LCA-PECy5 (eBioscience), anti-
F4/80-PECy7 (eBioscience), anti-CD11b-eF450 (eBioscience),
 
anti-MHC class II-APC 
(eBioscience), and anti-B220-eF780 (eBioscience). 
The gating strategies were described previously (235). Briefly, for the 
inflammatory leukocyte panel, CD11c+, LCA+ viable cells were displayed on a 
histogram of Gr-1 versus SigLecF. Neutrophils were defined as a distinct Gr-1 high, 
SigLecF+ cell population. The SigLecF+ subpopulation was then displayed on a 
histogram of CD11b versus CD11c, where eosinophils appeared as a CD11b high, CD11c 
low population, while resident macrophages were CD11b low and CD11c high. 
Excluding neutrophils and SigLecF high populations, the remaining CD11c+ cells were 
displayed on a plot of MHC class II versus B220. The B220 high, MHC class II low 
pDCs were excluded and the remaining cells were displayed on a plot of MHC class II 
versus CD11b; monocyte-derived DCs (or TIP-DCs) were the MHC class II low 
population, and inflammatory DCs (or CD11b high DCs) were MHC class II high and 
CD11b high. For the lymphocyte panel, viable lymphocytes (selected by forward/side 
scatter characteristics) were plotted on a histogram of CD3 versus autofluorescence, and 
the CD3+ cells were further displayed on a plot of CD4 versus CD8. B cells were defined 
as CD19+ and B220+ and NK cells were CD49b+ and NK1.1+. 
Immunohistochemistry (IHC) staining. Mock- and RRV-infected animals were 
sacrificed at 10 days post-infection and perfused with 4% paraformaldehyde, pH 7.3. 
Excised quadriceps tissues were embedded
 
in paraffin, and 5-µm sections were prepared. 
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To determine the extent of complement deposition in RRV-infected skeletal muscle, the 
tissues sections were deparaffinized in xylene, rehydrated through an ethanol gradient, 
and then probed with a goat anti-mouse C3 polyclonal antibody (1:500, Cappel) or a 
control goat IgG antibody using the Vectastain ABC-AP kit (Vector Labs, CA) and the 
Vector Blue alkaline phosphatase substrate kit (Vector Labs, CA) according to the 
manufacturers' instructions. Sections were then counterstained with Gill's hematoxylin. 
C3 deposition is indicated by a dark blue/violet stain within the tissues.  
Macrophage co-culture experiments. To perform in vitro co-culture experiments, one 
day old WT pups were sacrificed by decapitation, and skeletal muscle was extracted from 
the murine limbs for myocyte culture preparation. Muscle tissue was minced in a petri 
dish with 1 ml of HBSS+ buffer containing Hanks balanced salt solution (Gibco), 1% L-
glutamine (Mediatech) and 1/1000 Gentamicin (Sigma), and then 10 ml of 0.2% type II 
collagenase (Worthington Biochemicals) was added to the dish. The tissue samples were 
incubated in a 37ºC water bath for 30 min to 1 hour and vortexed every 10 min during the 
incubation period. The tissue samples were centrifuged at 3,000 rpm for 5 min, 
resuspended in warm DMEM (high glucose, Gibco) containing 6% FBS, 1/1000 
gentamicin and 1% L-glutamine, and then passed through a 70 µm cell strainer. Cells 
were plated in 24-well plates and incubated at 37ºC for 48-72 hours, after which the 
media was aspirated and replaced with high glucose DMEM containing 3% FBS, 1% L-
glutamine and 1/1000 gentamicin to induce tubule formation.  
Following myocyte differentiation, myocyte cultures were infected with RRV 
(MOI: 20) and incubated for 2 hours at 37ºC in a CO2 incubator. Bone-marrow 
macrophages obtained from WT and TLR4
-/- 
adult mice were then added to the myocytes 
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in a 1:1 ratio according to the myocyte seeding density and co-cultured for 10-16 hours at 
37ºC. At the indicated times post-infection, total RNA was isolated from the 
macrophages, reverse transcribed and analyzed for cytokine expression by quantitative 
Real-time PCR (RT-PCR) as described previously (235). Macrophage lysates were also 
examined for C3 activation by western blot analyses as described below. 
Western blotting. At 10 days post-infection, mock-infected and RRV-infected mice 
were sacrificed and perfused with 1× PBS. Quadriceps muscles were excised and 
homogenized in radioimmunoprecipitation lysis buffer (RIPA; 50 µM Tris pH 8.0, 150 
mM NaCl; 1% NP-40, 0.5% deoxycholate, 0.1% SDS and 1× complete protease inhibitor 
cocktail (Roche)). Protein concentration was determined by Bradford protein assay, and 
25–30 µg of total protein was loaded onto a 10% SDS-PAGE gel. The protein was 
transferred onto a PVDF membrane, and the membranes were blocked in 5% milk, 0.1% 
Tween-20 in PBS. The membranes were probed with a goat anti-mouse C3 polyclonal 
antibody (1:500, Cappel) or a goat anti-mouse actin polyclonal antibody (1:500, SCBT), 
washed with PBS containing 0.1% Tween-20, and incubated with a rabbit anti-goat 
antibody conjugated to horseradish peroxidase (1:10,000, Sigma). Following the antibody 
incubations, the membranes were washed and then developed by an ECL reagent kit 
(Amersham) according to the manufacturer's instructions to visualize the proteins.  
Statistical analyses. Data were analyzed using Prism software (GraphPad Software, 
Inc.). Comparisons of one-variable data were performed using a two-tailed unpaired 
Student’s t test. Percent starting weight for WT and TLR4-/- mice was analyzed using a 
one-way ANOVA with multiple comparisons corrections (P<0.01 is considered 
significant). Clinical scores for WT and TLR4
-/-
 mice were analyzed by Mann-Whitney 
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analysis with Bonferroni’s correction (P<0.01 is considered significant). Bar graphs 
represent mean values ± standard deviation. Significant differences are represented by 
comparison (*) with the following legend: *P≤0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001, unless otherwise indicated. 
 
4.4 Results 
 
TLR4 is required for RRV-induced disease  
Macrophages and complement, in particular mannose binding lectin (MBL), are 
required for alphavirus-induced arthritis and myositis (51, 56-59, 175). Moreover, we 
have previously shown that toll-like receptor (TLR) 7 signaling through the TLR adaptor 
molecule myeloid differentiation primary response gene 88 (Myd88) is critical for 
inducing protection from severe Ross River virus-induced disease in mice (235). 
However, many of the host pathways that are involved in alphavirus pathogenesis, 
including the role of other TLRs in the infection process, remain poorly understood. 
Because TLR4 has been shown to influence innate and adaptive immune responses to 
viral infection, we evaluated the role of TLR4 in a mouse model of RRV-induced 
arthritis/myositis (103, 105-108, 279, 280). TLR4-deficient (TLR4
-/-
) mice were highly 
resistant to RRV-induced disease, with TLR4
-/-
 mice showing significantly reduced 
disease signs, as measured by weight loss and disease scores, compared to wild-type 
(WT) C57BL/6J animals over the course of infection (Figure 4.1). Consistent with 
previous studies, RRV-infected WT mice lost weight between days 6 and 10 post-
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infection and reached peak disease scores (4.33 ± 0.29) at day 10 post-infection (Figure 
4.1). In contrast, TLR4
-/-
 mice continued to gain weight during the course of RRV 
infection, showing significantly increased weight gain at days 8, 9 and 10 days post-
infection compared to WT mice (Figure 4.1A).  Moreover, TLR4
-/- 
mice showed a 
delayed onset of disease signs and showed significantly reduced disease throughout the 
course of infection compared with WT mice (Figure 4.1B). Mock-infected animals of 
both strains showed similar weight gain and failed to show disease signs (data not 
shown). These results suggest that TLR4 plays a pathologic role during RRV infection 
and is critical for arthritogenic alphavirus-induced disease pathogenesis. 
Tissue damage during RRV infection is dependent on TLR4  
To determine whether TLR4 functioned to protect mice from RRV-induced tissue 
damage, we performed a histological analysis of skeletal muscle tissue from RRV-
infected WT and TLR4
-/- 
mice. Because WT mice reach peak clinical disease at 10 days 
post-RRV infection (53, 235), mice were sacrificed at this timepoint, and quadriceps 
tissues were removed for histological preparation. As shown in Figure 4.1C, TLR4
-/-
 mice 
showed significantly reduced skeletal muscle pathology compared to WT mice following 
RRV infection. While mock-infected animals of both strains showed similar levels of 
resident cellular infiltrates and intact muscle fibers, WT mice showed less intact muscle 
fibers and more overall tissue damage following RRV infection relative to TLR4
-/-
 mice 
(Figure 4.1C). 
To determine the degree of tissue damage present in the skeletal muscle at WT 
and TLR4
-/- 
mice, histological slides of RRV-infected quadriceps tissues were blinded 
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and scored using a blind scoring method based on the overall tissue pathology present in 
the tissues (Figure 4.1D). As shown in Figure 4.1D, the skeletal muscle of RRV-infected 
TLR4
-/-
 mice showed a drastic reduction in tissue damage compared with WT mice, with 
average damage scores in TLR4-deficient mice (2.5 ±1.0) significantly decreased relative 
to WT mice (6.8 ± 1.2) (Figure 4.1D). Therefore, these data suggest that TLR4 
contributes significantly to the skeletal muscle damage incurred during RRV infection.  
TLR4-deficient mice show reduced inflammatory leukocyte and NK cell recruitment at 
late times post-RRV infection  
Evaluation of histology slides demonstrated that RRV infection resulted in a 
significant reduction in the levels of virus-induced pathology (Fig 4.1D). There also 
appeared to be a reduction in the overall levels of inflammatory cell infiltration into these 
tissues (Fig. 4.1C). Therefore, to further evaluate this observation using quantitative 
methods, we used our established flow cytometry protocols (60, 235) to isolate, 
phenotype, and quantify the inflammatory cell infiltrates within the muscle of RRV-
infected TLR4
-/-
 and WT mice at 7 and 10 days post-infection. WT and TLR4
-/-
 mice 
showed no differences in the total numbers of LCA-positive cells in quadriceps tissues at 
both 7 and 10 days post-infection, indicating that the extent of tissue inflammation in WT 
and TLR4
-/-
 mice is similar following RRV infection (Figure 4.2A and 4.2C). At 7 days 
post-infection, WT and TLR4
-/-
 mice also showed similar levels of inflammatory 
leukocyte and lymphocyte cell populations, although TLR4
-/- 
mice showed a slight 
increase in B cells compared to WT mice (Figure 4.2A and 4.2B). However, analyses of 
infiltrating leukocyte and lymphocyte populations at 10 days post-infection revealed a 
significant decrease in the total numbers of neutrophils, resident macrophages, 
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plasmacytoid dendritic cells (DC)s, monocyte DCs and NK cells in the quadriceps of 
TLR4
-/-
 mice relative to WT mice (Figure 4.2C and 4.2D). These findings suggest that 
although WT and TLR4
-/-
 mice showed similar degrees of overall inflammation by flow 
cytometry, TLR4 deficiency may affect the recruitment of specific leukocyte and 
lymphocyte populations into the skeletal muscle at later times during RRV infection.   
Viral titers are similar between WT and TLR4-deficient mice following RRV infection  
We have previously shown that mice deficient in TLR7 or Myd88 showed 
increased viral titers relative to WT mice at late times post-RRV infection, which 
correlated with enhanced disease (235). To determine whether TLR4 deficiency altered 
viral loads during RRV infection, we assessed viral burden in the skeletal muscle and 
serum of RRV-infected WT and TLR4
-/-
 mice by plaque assay. As shown in Figure 4.3, 
WT and TLR4
-/- 
mice showed similar viral titers in the quadriceps and serum throughout 
the course of infection. No differences in viral burden were detected in the quadriceps 
tissues of WT and TLR4
-/-
 mice at 1, 2, 3, 5 and 7 days post-infection (Figure 4.3A). 
Moreover, WT and TLR4-deficient mice showed similar sera titers at 1, 2, and 3 days 
post-RRV infection (Figure 4.3B). Thus, RRV replication and clearance are similar in 
WT and TLR4
-/-
 mice, suggesting that TLR4 deficiency does not affect the kinetics of 
RRV infection and that viral replication is not responsible for the differences in disease 
observed between WT and TLR4
-/-
 mice.  
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Complement deposition and activation is decreased in RRV-targeted skeletal muscle of 
TLR4-deficient mice  
Viral replication and inflammatory cell recruitment was similar in target tissues of 
WT and TLR4-deficient mice despite significant differences in disease outcome. Given 
the role of complement in driving RRV-induced disease, we hypothesized that 
complement activation may be decreased in vivo in TLR4
-/-
 mice relative to WT mice 
during RRV infection. Therefore, we evaluated whether TLR4 was required for 
complement deposition in RRV-targeted skeletal muscle tissue by performing 
immunohistochemistry using a mouse-specific complement component 3 (C3) antibody. 
While mock-infected animals of both strains failed to show complement deposition, 
RRV-infected quadriceps tissues from TLR4
-/-
 mice showed a substantial reduction in C3 
deposition relative to WT mice at day 10 post-infection (Figure 4.4A). RRV-infected WT 
quadriceps tissue showed profuse C3 staining at areas of tissue damage following RRV 
infection, while the reduced complement deposition in TLR4
-/-
 murine tissues correlated 
with the decreased tissue damage observed in these mice (Figure 4.4A). Tissue sections 
incubated with a control goat IgG antibody showed no IgG deposition (data not shown). 
These results indicate that TLR4 mediates complement deposition in RRV-targeted 
skeletal muscle tissue during RRV infection in mice. 
Because TLR4-deficient mice exhibited decreased C3 deposition in quadriceps 
tissue compared to WT mice following RRV infection, we sought to determine whether 
the decreased complement deposition was leading to decreased complement activation in 
the knockout mice. Western blot analyses of quadriceps tissues from day 10-infected WT 
and TLR4-deficient mice indicated that C3 components, including the β chain of C3 and 
109 
the cleavage product iC3B, were reduced in the skeletal muscle of TLR4
-/-
 mice 
compared to WT mice following RRV infection (Figure 4.4B). These results indicate that 
complement deposition and activation are reduced in TLR4-deficient mice following 
RRV infection, and TLR4 may be essential for complement –dependent RRV 
pathogenesis.  
TLR4-deficient macrophages show reduced complement production following co-culture 
with RRV-infected myotubes  
Several studies have demonstrated that inflammatory macrophages contribute to 
RRV-induced pathogenesis (51, 56, 57, 60, 175, 281), and macrophages have been shown 
to be a source of localized complement production (282, 283). Because TLR4-deficient 
mice showed reduced complement deposition and activation in skeletal muscle following 
RRV infection, we sought to determine whether TLR4 regulated complement production 
by macrophages in response to RRV infection. Therefore, we developed a novel co-
culture assay in which primary myotube cultures derived from WT neonatal mice were 
infected with RRV and subsequently co-cultured with bone marrow-derived macrophages 
obtained from WT or TLR4
-/-
 adult mice, as indicated in Materials and Methods. RNA 
was then isolated from the co-cultured macrophages and analyzed for C3 expression 
using quantitative real-time PCR (qRT-PCR). WT macrophages upregulated C3 
expression in response to RRV-infected muscle cells (Figure 4.5A). Moreover, TLR4-
deficient macrophages showed significantly reduced C3 mRNA expression compared to 
WT macrophages following co-culture with RRV-infected myotubes (Figure 4.5A). We 
also assessed the expression of a panel of other genes whose expression has previously 
been linked to C3-dependent signaling, including IL-6, S100A8 and S100A9, and the 
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expression of these genes was also decreased in the absence of TLR4 (Figure 4.5B). In 
contrast, IL-1β, which is induced independently of C3 during RRV infection, was 
unaffected in TLR4 -deficient macrophages (Figure 4.5B). Importantly, the induction of 
C3 and C3-dependent gene expression was dependent on infectious virus as cultures 
incubated with heat-inactivated RRV or mock-infected controls did not induce 
macrophage activation (data not shown).  
To further assess whether TLR4 regulated C3 expression in response to RRV 
infection, we performed western blot analyses on the co-cultured WT and TLR4
-/-
 
macrophages to determine whether there were differences in downstream C3 activation. 
As shown in Figure 4.5C, complement activation components, including total C3, the α 
and β chains of C3, and iC3B, were all decreased in the TLR4-deficient macrophages 
compared to the WT macrophages following co-culture with RRV-infected myotubes 
(Figure 4.5C). Taken together, these findings demonstrate that complement activation in 
macrophages is dependent on TLR4 during RRV infection, suggesting that TLR4 
contributes to complement-mediated disease during RRV infection. 
 
4.5 Discussion 
 
Arthritogenic alphaviruses are known to activate innate immune components such 
as complement and macrophages, which are critical mediators of alphavirus-induced 
arthritis/myositis (51, 56-60, 175, 281). However, the mechanisms underlying the 
immune-mediated disease that is induced by alphavirus infection are poorly understood. 
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Previous work in our laboratory demonstrated that TLR pathways are involved in 
arthritogenic alphavirus-induced disease, showing that the Myd88-dependent TLR7 
signaling pathway mediates protection from severe RRV-induced disease and mortality in 
mice (235). The data presented in this work demonstrate that TLR4 is required for RRV 
pathogenesis in mice. Mice deficient in TLR4 exhibited decreased clinical morbidity and 
tissue damage compared to WT mice following RRV infection, despite showing similar 
levels of viral replication in target tissues. Furthermore, lack of TLR4 signaling resulted 
in a reduction in C3 production by macrophages within an in vitro myotube co-culture 
system, and TLR4 was also critical for complement deposition and activation in RRV-
targeted skeletal muscle tissue during infection. Therefore, these results identify TLR4 as 
an essential mediator of RRV pathogenesis and suggest that TLR4 may be therapeutic 
target for the treatment of arthritogenic alphavirus-induced disease. 
 TLR4 has been implicated to play protective and pathologic roles during other 
viral infections (100, 103-108, 279). Additionally, TLR4 plays a pathologic role in 
multiple human and mouse models of inflammatory arthritis (119-126). However, we are 
not aware of any studies that have demonstrated a role for TLR4 in the development of 
alphavirus-induced disease. Therefore, our findings present a novel role for TLR4 in 
promoting arthritogenic alphavirus-induced disease. Furthermore, these results indicate 
that in the absence of TLR4 signaling, the expression and activation of complement is 
significantly reduced in RRV infected tissues. Given that complement activation plays a 
major role in driving RRV-induced disease, these results suggest that TLR4 affects the 
virus-induced disease process at least in part by regulating localized complement 
production in response to RRV infection. However, at this time, we cannot rule out the 
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possibility that TLR4 might contribute to the virus-induced disease process through other 
mechanisms.     
Although we did not detect a role for viral replication in TLR4-dependent disease, 
we did detect slight but significant differences in cellular infiltration between WT and 
TLR4-deficient mice late during RRV infection (Fig. 4.2). The total numbers of specific 
cellular populations, including neutrophils, resident macrophages, plasmacytoid and 
monocytic DCs, and NK cells, were reduced in the skeletal muscle of TLR4-deficient 
mice at 10 days post-infection. Therefore, it is possible that TLR4 contributes to the 
inflammatory disease process in part by promoting the recruitment of inflammatory cells. 
However, it is important to note that at day 7 post-infection, which is a timepoint when 
we observed significantly decreased disease signs and tissue damage in the knockout 
mice, the TLR4-deficient mice did not exhibit any detectable alterations in inflammatory 
cell numbers. This suggests that TLR4 promotes disease through other mechanisms, such 
as inflammatory cell activation and subsequent induction of complement expression. This 
is supported by our in vitro assays, whereby we demonstrated that macrophages lacking 
TLR4 showed reduced expression of C3  following RRV infection (Fig 4.5). Moreover, 
complement activation was dependent on TLR4 in vivo in RRV-infected mice (Fig. 4.4). 
Previous studies have demonstrated that the expression of complement-dependent 
activation markers in human osteoarthritis patients is dependent on TLR4 (59, 60, 132, 
133), suggesting that TLR4 may play a role in complement-mediated arthritis in humans. 
However, it is currently unclear how TLR4 deficiency is affecting downstream defects in 
complement-mediated disease during RRV infection.  
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TLR4 is known to bind bacterial lipopolysaccharide via the TLR4-MD2 complex 
(284). Additionally, TLR4 recognizes other microbial components, including viral 
envelope proteins and other bacterial elements, although the structural mechanisms 
behind these molecular interactions have not been demonstrated (284). TLR4 signaling 
has also been shown to be modulated in a monocytic cell line through a direct interaction 
with MBL, which mediates complement-dependent disease during RRV infection (60, 
277, 278). Thus, it is possible that TLR4 is interacting with MBL during RRV infection, 
resulting in the downstream pathogenesis. Additionally, TLR4 has been shown to 
recognize the fusion (F) protein of respiratory syncytial virus (RSV), and the presence of 
the RSV F protein is necessary for TLR4-dependent inflammatory responses during RSV 
infection (99). Therefore, another possibility is that TLR4 is directly recognizing viral 
proteins during RRV infection to mediate downstream pathogenesis. Studies are ongoing 
in our laboratory to address the mechanism of TLR4-dependent activation during RRV 
infection.  
Given the protective role of TLR7 signaling during RRV infection, it is notable 
that another TLR pathway to virus-induced pathology during the same viral infection. 
Because TLR7 signals exclusively through Myd88 within endosomes while TLR4 signals 
from the plasma membrane and endocytic vesicles through multiple adaptors and 
pathways, it is possible that different pathways are activated downstream of these two 
TLRs following RRV infection(284). Both TLR pathways are known to stimulate NFkB 
pathways, leading to pro-inflammatory cytokine expression. However, TLR7 signaling 
also leads to interferon-stimulated gene expression via IRF7 activation, while TLR4 can 
activate IRF3- and AP1-dependent pathways. Alternatively, the essential, protective 
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effects of TLR7 may mask the pathologic role of TLR4, where both molecules signal 
through Myd88, thereby highlighting the value of using TLR specific knockouts to 
dissect their role in disease processes, rather than drawing conclusions from studies 
where downstream adaptors have been knocked out.  Additionally, it is possible that the 
roles of these TLRs are dependent on different cell types during RRV infection, such as B 
cells in the case of TLR7 and macrophages in the case of TLR4, and the kinetics of 
signaling through these TLRs may also differ during the course of RRV infection (93, 
235). Thus, we are currently performing experiments to address the downstream targets 
of differential TLR signaling during RRV infection to better understand their roles in 
virally induced disease. 
In summary, the results of this study demonstrate a pathologic role for TLR4 in 
the development of complement-mediated disease during RRV infection. These findings 
further elucidate the host inflammatory pathways that contribute to arthritogenic 
alphavirus-induced arthritis/myositis and identify TLR4 as a potential therapeutic target 
for the treatment of severe RRV-induced disease.   
115 
Figure 4.1 
 
Figure 4.1: TLR4 contributes to the development of RRV-induced disease in mice. 
Twenty-four day old C57BL/6J  wild-type (WT), and TLR4
-/-
 mice were subcutaneously 
infected in the left  rear footpad with either PBS diluent (Mock) or 10
3
 PFU of RRV and 
monitored for (A) weight loss and (B) clinical disease. N = 5-15 mice/strain/timepoint. 
*P<0.01, and *** P≤0.0001. Mice were sacrificed and perfused with 4% 
paraformaldehyde at 10 days post-infection. (C) & (D) Quadriceps muscles were excised 
and paraffin-embedded, and 5 µm tissue sections were stained with H&E. (C) 
Histological analysis of mock-infected and RRV-infected quadriceps muscles from WT 
and TLR4
-/- 
mice at day 10 post-infection. Representative images are shown. (D) Blind 
scoring of overall damage observed in RRV-infected WT and TLR4
-/- 
muscle tissue. N = 
11 (WT) and 7 (TLR4
-/-). ****P≤5E-7. 
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Figure 4.2 
 
Figure 4.2: TLR4-deficient mice show reduced numbers of inflammatory 
leukocyte and NK cell populations in RRV-infected quadriceps at late times post-
infection.  
Twenty-four day old WT and TLR4
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. At 7 and 10 days post-infection, mice were sacrificed and 
perfused with 1X PBS. Quadriceps muscles were excised, digested and prepared for flow 
cytometric analysis as described in Materials and Methods. (A) & (C) Total numbers of 
infiltrating inflammatory leukocyte cell populations isolated from RRV-infected WT and 
TLR4
-/- 
quadriceps muscle tissue. (B) & (D) Total numbers of infiltrating lymphocyte cell 
populations isolated from RRV-infected quadriceps muscle tissue. N = 4-7 
mice/strain/timepoint. *P≤0.01. 
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Figure 4.3 
 
Figure 4.3: Viral titers are similar between WT and TLR4-deficient mice 
following RRV infection.  
Twenty-four day old WT and TLR4
-/- 
mice were subcutaneously infected in the left rear 
footpad with 10
3
 PFU of RRV. At the indicated timepoints, mice were sacrificed by 
exsanguination and quadriceps tissues were dissected. Infectious virus present in (A) 
homogenized ipsilateral quadriceps tissue and (B) serum was quantified by plaque assay 
on Vero cells. N = 4-6 mice/strain/timepoint. *P≤0.05, **P≤0.01, ***P≤0.001. 
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Figure 4.4 
 
Figure 4.4: TLR4-deficient mice show reduced complement deposition and 
activation in RRV-infected muscle tissue.  
Twenty-four day old WT and TLR4
-/- 
mice were subcutaneously infected in the left rear 
footpad with either PBS diluent or 10
3
 PFU of RRV. (A) Mice were sacrificed and 
perfused with 4% paraformaldehyde at 10 days post-infection. Quadriceps muscles were 
excised and paraffin-embedded, and unstained 5 µm tissue sections were obtained for 
immunohistochemistry (IHC) and counterstained with Gill’s hemotoxylin as described in 
Materials and Methods. IHC staining for complement component 3 (C3) deposition in 
mock-infected and RRV-infected quadriceps muscles from WT and TLR4
-/- 
mice at day 
10 post-infection is indicated by dark blue/violet staining at areas of tissue damage. 
Representative images are shown. (B) Mice were sacrificed and perfused with 1X PBS at 
10 days post-infection. Quadriceps muscles were excised, homogenized and prepared for 
Western Blot analysis as described in Materials and Methods. Samples were assessed for 
complement activation products using an anti-mouse C3 antibody, and each lane 
represents a single animal. Images are representative of three separate experiments.  
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Figure 4.5 
 
Figure 4.5: TLR4-deficient macrophages show reduced complement production 
compared to WT macrophages following co-culture with RRV-infected myotubes. 
One day old WT mice were sacrificed by decapitation, and skeletal muscle was extracted 
for myocyte culture preparation as described in the Materials and Methods. Following 
myocyte differentiation, myotube cultures were infected with RRV (MOI: 20). At 2 hours 
post-infection, bone-marrow macrophages obtained from WT and TLR4
-/- 
adult mice 
were added to the myotubes and co-cultured for 16 hours. (A) & (B) At 18 hours post-
infection, total RNA was isolated from the WT and TLR4
-/- 
macrophages, reverse 
transcribed, and analyzed for (A) C3 and (B) inflammatory marker expression by 
quantitative Real-time PCR as described in Materials and Methods. Inflammatory 
markers analyzed included IL-1β, IL-6, s100A8, s100A9, Arg1, and TNF. (C) At 18 
120 
hours post-infection, cell lysates were harvested from the WT and TLR4-deficient 
macrophages and prepared for western blot analysis as described in Materials and 
Methods. Samples were assessed for complement activation products using an anti-
mouse C3 antibody, and each lane represents an individual sample. *P≤0.01, **P≤0.001. 
  
  
CHAPTER FIVE: 
DISCUSSION 
 
5.1 TLR7 mediates protection from severe RRV-induced disease 
 
TLR7 deficiency promotes antibody- and complement-mediated enhancement of RRV-
induced disease 
 Using in vitro analyses and animal models, multiple studies demonstrate the 
critical roles that innate immune pathways play in the development of arthritogenic 
alphavirus-induced disease. The primary innate immune mechanism that mediates 
protection from alphavirus pathogenesis is the type I IFN response (136). IFN induction 
is essential for controlling alphavirus replication and limiting virus infectivity, and mice 
with severe deficiencies in IFN signaling succumb rapidly to alphavirus infection (135, 
136). Furthermore, IRF3 and IRF7, which facilitate type I IFN and inflammatory 
cytokine production during viral infection, are required for protective IFN responses 
during lethal CHIKV and SINV infections, and ISGs induced through IFN signaling 
show potent antiviral effects during alphavirus infections (136, 148-151).  
Less is known about the precise mechanisms through which IFN and other 
inflammatory mediators are induced during alphavirus infection, although several sensing 
pathways are implicated. Cytoplasmic PRR activity via RIG-I, MDA5, and PKR is 
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thought to be important in mediating IFN induction and other antiviral responses during 
alphavirus infections (165, 179, 181, 183, 184). Furthermore, evidence suggests that the 
CLRs, DC-SIGN and L-SIGN, may be utilized by SINV for cell entry, and the DC 
inhibitory receptor DCIR plays a protective role in regulating inflammatory responses to 
CHIKV infection (187, 188). However, many studies implicating the roles of these PRRs 
in alphavirus pathogenesis were not effectively demonstrated in vivo, and the evidence 
from these studies suggests that multiple PRRs regulate the host response to alphavirus 
infection. 
The relative importance of TLRs to arthritogenic alphavirus infection is also 
poorly understood, although the TLR adaptors, Myd88 and TRIF show some role in 
protection from severe CHIKV dissemination and disease in mice (141, 150). Therefore, 
to determine whether TLR signaling played an essential role in arthritogenic alphavirus-
induced disease, we initially examined the role of the central TLR adaptor, Myd88 in a 
mouse model of alphavirus-associated arthritis/myositis. The results of our initial study 
demonstrated that Myd88 signaling is a critical mediator of host defense during RRV 
infection and functioned to protect mice from severe RRV-induced skeletal muscle 
damage and mortality. Furthermore, we found that Myd88 signaling was dependent on 
TLR7 during RRV infection, and Myd88-dependent TLR7 signaling was required for the 
development of RRV-specific neutralizing antibody responses. Our findings were the 
first to establish the critical function of Myd88-dependent TLR7 signaling in mediating 
protective adaptive immune responses to arthritogenic alphavirus infection and revealed 
the importance of TLR pathways in the host defense against alphavirus-induced disease. 
Because Myd88-deficient mice were previously found to be more susceptible to CHIKV 
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dissemination but not CHIKV-induced mortality, these findings suggest that Myd88-
dependent TLR signaling plays an important protective role in arthritogenic alphavirus 
infection, but the relative significance of this pathway may be contingent on the 
experimental approach or mouse model used (141). 
As a follow-up to our previous study, we sought to determine the mechanism of 
RRV-induced disease exacerbation in the absence of Myd88-dependent TLR7 signaling. 
Because mice deficient in TLR7 produced high titers of low affinity, non-neutralizing 
RRV-specific antibodies, we assessed whether the antibodies produced in the absence of 
TLR7 were pathologic and found that TLR7- and Myd88-deficient mice were susceptible 
to severe antibody- and complement-dependent RRV-induced disease. This study was the 
first to demonstrate that Myd88-dependent TLR7 signaling protects mice from systemic 
complement-mediated immune complex disease during RRV infection. Further studies 
will be necessary to determine whether the mechanism of Myd88-mediated protection 
from CHIKV dissemination is also dependent on antibody responses to infection.  
Insights into mechanisms of TLR7-mediated protection 
 The importance of TLR7 signaling to the development of RRV-specific 
neutralizing antibodies contributes to our insight into the mechanism of TLR7-mediated 
protection from RRV-induced disease. Although it is not currently known whether TLR7 
signaling modulates B cell activity through a direct or indirect mechanism in our model, 
it is clear that TLR7 deficiency results in an inability to form splenic germinal centers 
and generates defective antibody responses during RRV infection. Because TLR7 
signaling in DCs can regulate adaptive immune responses to viral infection via IFN 
production, we examined type I IFN levels in the sera of RRV-infected WT, TLR7- and 
124 
Myd88-deficient mice and found no differences in type I IFN expression across the 
infected strains (Figure 2.4) (202, 222, 224, 225). Furthermore, pDCs isolated from 
TLR7
-/-
 mice showed no defect in type I IFN production in response to RRV infection 
(Figure 5.1). Thus, it is possible that TLR7 signaling may alter the function of DCs or 
other antigen-presenting cells by affecting their ability to activate B cells via antigen 
presentation and/or cytokine secretion, which could lead to defective B cell responses to 
RRV infection. Alternatively, because CD4+ T cells also express TLR7 and were 
significantly reduced in the skeletal muscle of TLR7-deficient mice late during RRV 
infection, TLR7 deficiency may affect CD4+ T cell activation and/or localization during 
infection, which can also modulate neutralizing antibody responses (82, 221).  
However, evidence from other studies suggests that TLR7 signaling may function 
directly within B cells to modulate antibody maturation during viral infection (80). 
Recent studies demonstrated that Myd88-dependent TLR7 signaling is required for 
neutralizing antibody responses during vaccination and viral infections, and specific 
depletion of Myd88 in B cells results in the ablation of neutralizing antibody responses 
and a corresponding loss in protection from Friend virus infection (93, 96). Evidence 
suggests that B cell intrinsic TLR signaling can stimulate the development of germinal 
center B cells, which promote high-affinity, neutralizing antibody production, via two 
mechanisms (285). First, the combined activation of B cell receptors (BCR) and TLRs 
can induce germinal center differentiation in antigen-specific B cells. Second, the 
combination of BCR and TLR stimulation in germinal center B cells may function 
synergistically to promote somatic hypermutation and enhance the production of high-
affinity IgG. Furthermore, TLR stimulation in activated B cells induces class switch 
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recombination through deaminase upregulation and may promote isotype switching from 
Th2-associated IgG1 to Th1-associated IgG2 (80, 285). The demonstration in our study 
that TLR7-deficient mice exhibited a skewed Th1/Th2 RRV-specific antibody response 
further supports the evidence that Myd88-dependent TLR7 signaling in B cells is 
required for efficient IgG class switching and protective antibody responses during 
infection. However, studies using tissue-specific depletions of Myd88 will be necessary 
to confirm whether intrinsic Myd88-dependent signaling in B cells is required for 
protection from severe RRV-induced disease. 
In addition to its role in promoting protective antiviral antibody responses, our 
findings demonstrated that Myd88-dependent TLR7 signaling protects mice from 
myocardial tissue damage following RRV infection. Because Myd88- and TLR7-
deficient animals also exhibited antibody and complement deposition in infected cardiac 
tissues, our results suggest that TLR7 deficiency promotes cardiac disease via antibody- 
and complement-mediated mechanisms. Previous studies have shown that Myd88 is 
essential for TLR-dependent anti-apoptotic signaling in myocardioctyes (286). Thus, it is 
also possible that deficiency in TLR7 signaling may result in cellular apoptosis of 
infected myocardial tissues, which can activate complement via damage-associated 
molecular patterns that are presented in apoptotic cells (234). However, the focal 
localization of the cardiac pathology, which corresponds to the focal staining of antibody 
and complement deposition, suggests that the cardiac damage incurred during RRV 
infection is associated with both antibody- and complement-dependent mechanisms of 
disease (Figures 3.3 and 3.4). Moreover, TLR7-deficient mice exhibited enhanced 
complement-associated pro-inflammatory marker expression in myocardial tissues 
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(Figure 3.3), and the expression of these markers is associated with cardiac suppression 
(244-248). To determine whether myocardial function is defective during RRV infection 
in the absence of TLR7 signaling, cardiomyocyte contractile function can be assessed by 
measuring cardiac ventricular pressures in RRV-infected WT, TLR7- and Myd88-
deficient mice (287). Further investigation will be necessary to determine whether the 
cardiac injury induced in RRV-infected Myd88- and TLR7-deficient mice is sufficient to 
induce heart failure and/or decreased blood flow in these mice, which could lead to organ 
failure, or whether other factors are responsible for the mortality observed in these 
animals during RRV infection (288). 
It is currently unclear from our study what PAMPs or signals regulate TLR7 
signaling during alphavirus infection. Because TLR7 recognizes ssRNA, it is plausible 
that alphavirus genomic ssRNA exposed during viral uncoating in the endosome may 
trigger TLR7 responses upon infection (64). An alternative mechanism of TLR7 
activation could be through RNA intermediates generated during viral replication, which 
could be trafficked to the endosome (via autophagy or other mechanisms) to stimulate 
TLR7. Follow-up studies will be necessary to determine which signals regulate TLR7 
signaling during RRV infection. 
Future directions 
 Myd88-deficient mice showed significant antibody and complement deposition 
and pathology in cardiac and renal tissues during RRV infection, and the enhancement of 
RRV-induced disease appears to be dependent on the C1q-dependent classical pathway 
of the complement cascade. However, we have not yet established whether Myd88- and 
TLR7-deficient mice exhibit enhanced C1q-bound immune complexes in the sera during 
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RRV infection, which could deposit systemically and is indicative of traditional serum 
sickness, or whether the antibody generated is deposited into tissues and results in local 
complement activation. To determine whether circulating immune complexes and/or 
complement activity is elevated in the sera in the absence of Myd88-dependent TLR7 
signaling, sera from RRV-infected WT, Myd88
-/-
, and TLR7
-/-
 mice can be subjected to a 
C1q-binding assay, which is a quantitative method for measuring C1q binding to 
antibody-containing complexes, or a complement consumption assay, which measures 
total complement reactivity to the sera (289-291). Furthermore, because severe 
arthritogenic alphavirus-induced disease can be associated with autoantibody production, 
it would be interesting to determine whether the antibodies detected in non-RRV targeted 
cardiac and renal tissues of Myd88- and TLR7-deficient mice can cross-react with host 
antigens or whether they are only specific for RRV (48, 232, 249, 258, 292). 
Levels of C3a, a marker of C3 cleavage and complement activation, are elevated 
in the synovial fluid of RRV-infected polyarthritis patients (58). Because RRV-induced 
disease in the context of normal TLR7 signaling is associated with MBL and the lectin 
pathway of complement activation, it would not be expected that human patients infected 
with RRV would suffer from complement-dependent immune complex disease (60). In 
fact, a study from our laboratory demonstrated that serum and synovial MBL levels 
correlated with the severity of disease in RRV-infected patients, while the levels of C1q-
C4 complexes, which are indicative of classical complement activation, were similar in 
the synovial fluid of patients with severe and mild cases of RRV-induced disease (60, 
290). However, the same study demonstrated that levels of the complement cleavage 
product, C4a, which can result from activation of the lectin or classical pathways, were 
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elevated in the synovial fluid of patients with severe RRV-induced polyarthritis 
compared to patients with mild disease, and it would be interesting to know whether 
levels of C1q-C4 complexes or IgG complexes are elevated in the sera of RRV-infected 
patients (60). Furthermore, our findings suggest that RRV-infected patients with defects 
in Myd88-dependent TLR7 signaling because of genetic polymorphisms in the genes 
associated with signal transduction may be at increased risk for developing C1q-
associated immune complex disease, and targeted treatment of complement-induced 
disease via C3 or C1q inhibitors may provide therapeutic benefits to these patients (293). 
Larger human cohort studies will be necessary i) to determine whether immune complex 
disease can occur in RRV-infected patients and if so, ii) to evaluate the efficacy of 
complement-directed therapies in this subset of individuals. 
In addition, studies have demonstrated that patients with severe rheumatoid 
arthritis have elevated levels of MBL and C1q-associated immune complexes (291, 294). 
Moreover, the inflammatory gene profiles of CHIKV- and RA-induced diseases are 
significantly similar, and evidence suggests that chronic CHIKV infection may lead to 
RA and autoantibody production in some patients (171, 295-297). Because prolonged 
alphavirus-induced arthropathy can lead to the development of autoantibodies and 
possibly rheumatic diseases, it would be beneficial to examine whether C1q-associated 
immune complexes are elevated in patients with chronic arthritogenic alphavirus-induced 
disease (292, 295, 297). Additionally, anti-rheumatic drugs (ARDs) such as sulfasalazine 
and methotrexate show considerable efficacy in treating patients with chronic CHIKV-
induced polyarthritis (297). If patients with chronic arthritogenic alphavirus-induced 
disease also demonstrate enhanced C1q-associated immune complexes, combinatorial 
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treatments using ARDs and C1q inhibitors may provide therapeutic benefits in treating 
these patients. 
 
5.2 TLR4 promotes RRV pathogenesis 
 
TLR4 induces complement-mediated disease during RRV infection 
Our studies evaluating the role of Myd88 and TLR7 in RRV-induced disease 
demonstrated that TLR signaling plays an essential role in arthritogenic alphavirus 
pathogenesis. However, it remained unclear whether other TLR pathways could be 
involved in alphavirus-induced disease. Thus, we directed our subsequent investigation to 
screen other TLR pathways using our mouse model of RRV-induced arthritis/myositis. 
Because TLR4 has shown important functions in a number of viral infections and in 
inflammatory arthritis, we evaluated the role of TLR4 during RRV infection and found 
that mice lacking TLR4 were resistant to RRV-induced disease. TLR4-deficient mice 
showed decreased complement activation and decreased skeletal muscle damage 
compared to WT mice following RRV infection, and TLR4-deficient macrophages 
showed deficiencies in complement activation following co-culture with RRV-infected 
muscle cells. Our findings are the first to demonstrate that i) TLR4 is required for the 
development of complement-mediated tissue damage during RRV infection, and ii) 
TLR4 signaling in macrophages regulates complement activation during RRV infection.  
MBL, which is known to mediate RRV-induced inflammatory disease, has been 
shown to modulate TLR4 signaling in a macrophage cell line (60, 277, 278). Because 
these studies were investigated in vitro and have not been reported in the context of 
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infection, we sought to determine whether MBL could contribute to macrophage 
activation during RRV infection and if so, whether TLR4 signaling in macrophages was 
modulated by MBL following co-culture with RRV-infected muscle cells. Using our co-
culture system, we demonstrated that macrophages lacking MBL showed decreased 
expression of C3 and other complement-associated pro-inflammatory markers compared 
to WT macrophages following co-culture with RRV-infected myotubes (Figure 5.2). 
Moreover, complement-associated activation markers were reduced in MBL- and TLR4-
deficient macrophages, while levels of IL-1β expression were similar between WT, MBL-
/-
, and TLR4
-/-
 macrophages (Figure 5.2). In a follow-up study, we incubated co-cultured 
WT and TLR4-deficient macrophages with sera from WT or MBL-deficient mice and 
examined whether the sera (as a source of MBL) modulated C3 expression in 
macrophages during RRV infection. As shown in Figure 5.3, treatment with MBL-
containing sera resulted in enhanced C3 expression in WT macrophages but did not affect 
C3 expression in TLR4-deficient macrophages following co-culture with RRV-infected 
myotubes (Figure 5.3). However, incubation with WT and MBL-deficient sera caused 
enhanced activation of WT and TLR4
-/-
 macrophages that was independent of MBL (data 
not shown), and future studies should utilize purified MBL to avoid non-specific effects 
of the sera on macrophage activation. Taken together, these results suggest that MBL 
may modulate macrophages in a TLR4-dependent manner during RRV infection. 
Previous studies demonstrated that the N-linked glycans on the RRV E1 and E2 
glycoproteins contribute to type I IFN induction in DCs (40, 185). Additionally, evidence 
in our laboratory suggests that complement-mediated disease during RRV infection is 
dependent on the viral glycans because studies with RRV mutant viruses lacking the E1 
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and E2 envelope glycans showed reduced morbidity and complement activation in mice 
(Gunn and Heise, unpublished). Because complement activation was reduced in TLR4-
deficient mice and macrophages during RRV infection, we hypothesized that the RRV 
envelope glycans may contribute to complement activation in a TLR4-dependent manner. 
Thus, we co-cultured macrophages from WT or TLR4
-/-
 mice with primary myotubes that 
were infected with either RRV or an RRV mutant lacking the two glycans on the E2 
glycoprotein (RRV-DM) (40). The results from the co-culture experiments revealed that 
the RRV-DM virus induced significantly less C3 and pro-inflammatory expression in WT 
macrophages than RRV (Figure 5.2). However, the expression of C3 and C3-associated 
inflammatory markers was similar between TLR4-deficient macrophages following 
infection with either RRV or RRV-DM, suggesting that glycan-mediated complement 
activity is dependent on TLR4 expression. Furthermore, because our previous studies 
indicated that TLR4-dependent macrophage activation may be modulated by MBL, we 
examined whether glycan-dependent macrophage activation was also dependent on MBL 
and found that MBL-deficient macrophages showed similar C3 and C3-associated pro-
inflammatory marker expression following infection with either RRV or RRV-DM 
(Figure 5.2). These findings suggest that RRV-induced complement activation in 
macrophages is dependent on TLR4, MBL, and the viral envelope glycans. 
Insights into mechanisms of TLR4-induced pathogenesis 
Macrophages and complement contribute to arthritogenic alphavirus 
pathogenesis, and evidence suggests that macrophages may contribute to complement-
mediated disease through localized complement production during RRV infection (51, 
56, 57, 60, 175, 281). Additionally, the data derived from our in-vitro co-culture analyses 
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indicated that the expression of C3 and C3-associated pro-inflammatory markers in co-
cultured macrophages were dependent on TLR4, MBL, and the viral envelope glycans, 
and complement expression in macrophages may be modulated by MBL in a TLR4-
dependent manner during RRV infection. Using the data derived from co-culture system, 
we propose potential mechanisms of TLR4-induced disease during RRV infection. 
Firstly, MBL binds microbial carbohydrates, and evidence suggests that MBL may bind 
to the N-linked glycans on RRV glycoproteins to activate the lectin pathway of the 
complement cascade during RRV infection [(60, 234), and Gunn & Heise, unpublished]. 
Because MBL can directly interact with TLR4 and modulate macrophage activation, our 
data suggest that MBL may bind to TLR4 on macrophages and enhance TLR4 signaling 
during RRV infection, leading to increased complement activation and inflammation 
(277, 278). However, TLR4 can also be directly activated by viral glycoproteins, and it is 
possible that RRV envelope glycans interact with TLR4 through an MBL-independent 
mechanism to induce TLR4 activation (99-102). Further investigation will be necessary 
to determine whether MBL and/or the viral envelope glycans interact directly with TLR4 
to mediate downstream pathogenesis during RRV infection. 
Because TLR4 is known to signal through Myd88, it is noteworthy that TLR4
-/-
 
mice are resistant to RRV-induced disease, while Myd88
-/-
 mice show enhanced 
susceptibility to RRV-induced morbidity and mortality. Because Myd88-dependent 
TLR7 signaling is critically important for protection from adaptive immune dysregulation 
during RRV infection, the role of Myd88-dependent TLR4 signaling during RRV 
infection may be less critical in comparison, and the cell types within which these TLR 
pathways function during RRV infection (i.e. B cells and macrophages, for example) may 
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also differ. However, it is also possible that the TLR4 signaling induced during RRV 
infection occurs independently of Myd88 via the TRAM-TRIF endosomal pathway of 
TLR4 activation (75). Interestingly, mice deficient in the other TLR4-associated 
adaptors, including TRIF
-/-
, TIRAP
-/-
, and TRAM
-/-
 mice, showed a similar disease 
progression to WT mice following RRV infection (Neighbours, Long and Heise, 
unpublished). Thus, RRV-induced TLR4 signaling may be redundant through TRIF and 
TRAM, and future studies could address whether mice deficient in both TRIF and TRAM 
(TRIFxTRAM DKO mice) show a similar phenotype to TLR4-deficient mice following 
RRV infection. 
Future directions 
TLR4-deficient mice showed reduced complement deposition and activation in 
RRV-infected skeletal muscle tissue, and in vitro co-culture experiments demonstrated 
that complement activation in macrophages is dependent on TLR4 during RRV infection. 
However, our studies have not conclusively demonstrated that TLR4 signaling 
contributes to macrophage-dependent complement activation in vivo. It is possible that 
TLR4 deficiency in macrophages results in reduced expression of other pro-inflammatory 
markers, which we also observed in vitro, and the resulting decrease in macrophage 
cytokine secretion may reduce the activation of other effector cells that could mediate 
RRV-induced complement deposition and disease. Alternatively, TLR4 signaling may 
regulate complement deposition by macrophages during RRV infection, but other cell 
types such as NK cells may mediate the cytotoxicity that contributes to tissue damage 
during RRV infection (298). Our in vitro analyses suggested that TLR4 deficiency does 
not affect macrophage cytotoxicity as measured by nitric oxide and LDH release 
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following co-culture with RRV-infected myotubes (Figure 5.4), indicating that perhaps 
other cell types mediate cytotoxicity during RRV infection. However, because the in vitro 
co-culture system lacks the complexity of in vivo inflammatory processes and 
interactions, future studies should examine the impact of TLR4 signaling on macrophage 
cytotoxicity in RRV-infected mice. Moreover, follow-up studies will be necessary to 
confirm whether TLR4 deficiency affects complement activity in macrophages during in 
vivo RRV infection. 
TLR4 activation is associated with pathologic outcomes in a number of chronic 
human inflammatory disorders, including arthritis (299). One of the therapeutic 
implications of our findings is that treating RRV-infected patients with pharmacological 
TLR4 antagonists may ameliorate RRV-induced disease. Eritoran is a synthetic lipid A 
that binds to MD2 within the TLR4 complex to antagonize TLR4 signaling, and 
administration of eritoran has shown efficacy in treating TLR4-induced inflammation 
(299). Alternatively, drugs that target reactive oxygen species or nitric oxides, which are 
induced by TLR4 signaling, may also reduce inflammation resulting from TLR4 
activation. Future studies should examine whether treatment with drugs that directly or 
indirectly prevent TLR4 signaling reduces RRV-induced inflammatory disease. 
Additionally, because TLR4 signaling induces complement activation during RRV 
infection, drugs that directly target complement components or prevent complement 
activation may provide therapeutic benefits to RRV-infected patients. 
5.3 Conclusions 
In summary, host inflammatory pathways contribute to the development of 
arthritogenic alphavirus-induced disease, but many of the mechanisms underlying the 
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inflammation have not been elucidated. The work described in this dissertation 
demonstrates that TLR signaling significantly contributes to arthritogenic alphavirus 
pathogenesis, and TLR activation can lead to protective or pathologic outcomes during 
RRV infection. Our studies also demonstrate that TLR pathways regulate multiple 
components of RRV-induced disease, including complement activation. The role of 
Myd88-dependent TLR7 signaling in mediating protective antibody responses during 
RRV infection, other viral infections, and vaccinations suggests that targeting this 
pathway through TLR7 agonists may enhance therapeutic strategies designed to prevent 
or treat alphavirus infections. In contrast, specific strategies designed to block TLR4 
signaling may prevent chronic inflammatory disease in RRV-infected patients. Further 
investigation will be necessary to determine whether TLR pathways contribute 
significantly to alphavirus-induced inflammatory arthritis in humans. 
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Figure 5.1 
 
Figure 5.1: Plasmacytoid DCs from WT and TLR7
-/-
 mice produce similar 
amounts of type I IFN following RRV infection. 
Plasmacytoid DCs (pDCs) were isolated from adult WT and TLR7
-/-
 mouse spleens using 
anti-mPDCA-1 microbeads (Miltenyi Biotec) and the autoMACS columns (Miltenyi 
Biotec), according to the manufacturer’s instructions. Isolated pDCs were plated and 
infected with RRV (MOI: 20) for 12 hours, and supernatants were analyzed for type I 
IFN production by IFN Bioassay as described above (Chapter 2, Materials and Methods). 
N = 4 (WT) or 5 (TLR7
-/-
) replicate samples per strain. 
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Figure 5.2 
 
Figure 5.2: Expression of complement-associated inflammatory markers is 
reduced in TLR4- and MBL-deficient macrophages following co-culture with RRV-
infected but not RRV-DM-infected myotubes. 
One day old WT mice were sacrificed by decapitation, and skeletal muscle was extracted 
for myocyte culture preparation as described above (Chapter 4, Materials and Methods). 
Following myocyte differentiation, myotube cultures were infected with RRV or RRV-
DM (MOI: 20). At 2 hours post-infection, bone-marrow macrophages obtained from WT, 
TLR4
-/-
, and MBL
-/-
 adult mice were added to the myotubes and co-cultured for 16 hours. 
Total RNA was isolated from the macrophages, reverse transcribed, and analyzed for C3 
and inflammatory marker expression by quantitative Real-time PCR. Inflammatory 
markers analyzed included IL-1β, IL-6, s100A8, s100A9, Arg1, and TNF.  
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Figure 5.3 
 
Figure 5.3: MBL treatment enhances C3 expression in WT macrophages but not 
TLR4-deficient macrophages following co-culture with RRV-infected myotubes. 
One day old WT mice were sacrificed by decapitation, and skeletal muscle was extracted 
for myocyte culture preparation as described above (Chapter 4, Materials and Methods). 
Following myocyte differentiation, myotube cultures were infected with RRV (MOI: 20). 
At 2 hours post-infection, bone-marrow macrophages obtained from WT and TLR4
-/-
 
adult mice were added to the myotubes and co-cultured for 14 hours. At 16 hours post-
infection, sera from WT or MBL
-/-
 mice were diluted 1:10 in media and incubated on the 
cultures for 2 hours. Total RNA was isolated from the macrophages, reverse transcribed, 
and analyzed for C3 expression by quantitative Real-time PCR. N = 3 replicate 
samples/strain/treatment. 
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Figure 5.4 
 
Figure 5.4: Macrophage cytotoxicity is not impacted by TLR4 signaling following 
co-culture with RRV-infected myotubes. 
One day old WT mice were sacrificed by decapitation, and skeletal muscle was extracted 
for myocyte culture preparation as described in the Materials and Methods. Following 
myocyte differentiation, myotube cultures were infected with RRV (MOI: 20). At 2 hours 
post-infection, bone-marrow macrophages obtained from WT and TLR4
-/- 
adult mice 
were added to the myotubes and co-cultured for 10 hours. (A) & (B) At 12 hours post-
infection, cytotoxicity of the macrophage-myotube co-cultures was determined by ELISA 
using (A) NOS production and (B) LDH release in the infected supernatants as measures 
of cytotoxicity. Data is expressed over mock-infected cultures. 
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